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A B S T R A C T
Background
The 8-aminoquinoline (8AQ) drugs act on Plasmodium falciparum gametocytes, which transmit malaria from infected people to
mosquitoes. In 2012, theWorld HealthOrganization (WHO) recommended a single dose of 0.25 mg/kg primaquine (PQ) be added to
malaria treatment schedules in low-transmission areas or those with artemisinin resistance. This replaced the previous recommendation
of 0.75 mg/kg, aiming to reduce haemolysis risk in people with glucose-6-phosphate dehydrogenase deficiency, common in people
living in malarious areas. Whether this approach, and at this dose, is effective in reducing transmission is not clear.
Objectives
To assess the effects of single dose or short-course PQ (or an alternative 8AQ) alongside treatment for people with P. falciparummalaria.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL), published in the Cochrane Library; and the WHO International Clinical Trials Registry Platform (ICRTP) portal using
‘malaria*’, ‘falciparum’, ‘primaquine’, ‘8-aminoquinoline’, and eight 8AQ drug names as search terms. We checked reference lists of
included trials, and contacted researchers and organizations. Date of last search: 21 July 2017.
Selection criteria
Randomized controlled trials (RCTs) or quasi-RCTs in children or adults, adding PQ (or alternative 8AQ) as a single dose or short
course alongside treatment for P. falciparum malaria.
Data collection and analysis
Two authors screened abstracts, applied inclusion criteria, and extracted data. We sought evidence on transmission (community
incidence), infectiousness (people infectious and mosquitoes infected), and potential infectiousness (gametocyte measures assessed by
microscopy or polymerase chain reaction [PCR]). We grouped trials into artemisinin and non-artemisinin treatments, and stratified
by PQ dose (low, 0.2 to 0.25 mg/kg; moderate, 0.4 to 0.5 mg/kg; high, 0.75 mg/kg). We used GRADE, and absolute effects of
infectiousness using trial control groups.
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Main results
We included 24 RCTs and one quasi-RCT, comprising 43 arms. Fourteen trials evaluated artemisinin treatments (23 arms), nine trials
evaluated non-artemisinin treatments (13 arms), and two trials included both artemisinin and non-artemisinin arms (three and two
arms, respectively). Two trial arms used bulaquine. Seven PQ arms used low dose (six with artemisinin), 11 arms used moderate dose
(seven with artemisinin), and the remaining arms used high dose. Fifteen trials tested for G6PD status: 11 excluded participants with
G6PD deficiency, one included only those with G6PD deficiency, and three included all, irrespective of status. The remaining 10 trials
either did not test or did not report on testing.
No cluster trials evaluating community effects on malaria transmission met the inclusion criteria.
With artemisinin treatment
Low dose PQ
Infectiousness (participants infectious to mosquitoes) was reduced (day 3 or 4: RR 0.12, 95% CI 0.02 to 0.88, 3 trials, 105 participants;
day 8: RR 0.34, 95% CI 0.07 to 1.58, 4 trials, 243 participants; low certainty evidence). This translates to a reduction in percentage of
people infectious on day 3 or 4 from 14% to 2%, and, for day 8, from 4% to 1%; the waning infectiousness in the control group by
day 8 making the absolute effect smaller by day 8. For gametocytes detected by PCR, there was little or no effect of PQ at day 3 or
4 (RR 1.02, 95% CI 0.87 to 1.21; 3 trials, 414 participants; moderate certainty evidence); with reduction at day 8 (RR 0.52, 95% CI
0.41 to 0.65; 4 trials, 532 participants; high certainty evidence). Severe haemolysis was infrequent, with or without PQ, in these groups
with few G6PD-deficient individuals (RR 0.98, 95% CI 0.69 to 1.39; 4 trials, 752 participants, moderate certainty evidence).
Moderate dose PQ
Infectiousness was reduced (day 3 or 4: RR 0.13, 95% CI 0.02 to 0.94; 3 trials, 109 participants; day 8 RR 0.33, 95% CI 0.07 to 1.57;
4 trials, 246 participants; low certainty evidence). Illustrative risk estimates for moderate dose were the same as low dose. The pattern
and level of certainty of evidence with gametocytes detected by PCR was the same as low dose, and severe haemolysis was infrequent
in both groups.
High dose PQ
Infectiousness was reduced (day 4: RR 0.2, 95% CI 0.02 to 1.68, 1 trial, 101 participants; day 8: RR 0.18, 95% CI 0.02 to 1.41, 2
trials, 181 participants, low certainty evidence). The effects on gametocyte prevalence showed a similar pattern to moderate and low
dose PQ. Trials did not systematically report evidence of haemolysis.
With non-artemisinin treatment
Trials with non-artemisinin treatment have been conducted only for moderate and high dose PQ. With high dose, infectiousness
appearedmarkedly reduced on day 5 (RR 0.09, 95%CI 0.01 to 0.62; 30 participants, very low certainty evidence), with similar reductions
at day 8. For both moderate dose (two trials with 221 people) and high dose (two trials with 30 people), reduction in gametocytes
(detected by microscopy) showed similar patterns as for artemisinin treatments, with little or no effect at day 4 or 5, and larger effects
by day 8. No trials with non-artemisinin partner drugs systematically sought evidence of severe haemolysis.
Two trials comparing bulaquine with PQ suggest bulaquine may have larger effects on gametocytes by microscopy on day 8 (RR 0.41,
95% CI 0.26 to 0.66; 2 trials, 112 participants).
Authors’ conclusions
A single low dose of PQ (0.25 mg/kg) added to artemisinin-based combination therapy for malaria reduces infectiousness of people to
mosquitoes at day 3-4 and day 8, and appears as effective as higher doses. The absolute effect is greater at day 3 or 4, and smaller at
day 8, in part because of the lower infectiousness in the control group. There was no evidence of increased haemolysis at 0.25 mg/kg,
but few G6PD-deficient individuals were included in the trials. The effect on infectiousness precedes the effect of PQ on gametocyte
prevalence. We do not know whether single dose PQ could reduce malaria transmission at community level.
P L A I N L A N G U A G E S U M M A R Y
A single dose of primaquine added to malaria treatment to prevent malaria transmission
What is the aim of this review?
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To assess the effects of adding a single dose of primaquine (PQ) to treatment for falciparum malaria to reduce disease transmission.
This Cochrane Review update includes 25 controlled trials. The date of latest search was 21 July 2017.
Key messages
A single low dose of PQ, at 0.25 mg/kg, which the World Health Organization (WHO) recommends adding to artemisinin-based
combination therapy for malaria, reduces infectiousness (transmission from people to mosquitoes). In the trials, the percentage of
people who infected mosquitoes three to four days after treatment was reduced from 14% to 2%, with a smaller effect at day 8, from
4% to 1%, with no evidence of harm.
What was studied in the review
PQ kills gametocytes (malaria transmission stages) of the falciparum malaria parasite. Gametocytes infect mosquitoes during a bite,
thus perpetuating transmission. There is concern that PQ may cause red blood cells to burst (haemolysis) in people with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, a genetically-determined condition common in many malaria-endemic settings, which
can lead to anaemia. Recognizing concerns about the risk of haemolysis, the WHO reduced the recommended PQ dose from 0.75 mg/
kg to 0.25 mg/kg in 2012.
Ideally, this approach would be tested by randomly assigning villages to standard malaria treatment, or standard treatment plus a low
dose of PQ, then measuring the effect on malaria over time but this would be difficult and expensive. So, indirect indicators are used to
shed light on effectiveness, including feeding studies, in which mosquitoes are allowed to feed on people (or their blood), comparing
those who were assigned PQ with those who were not. Alternatively, researchers may simply monitor the presence (prevalence), number
(density), and duration (time of persistence) of gametocytes in the blood of people after different treatments, assuming that gametocytes
are viable irrespective of exposure to PQ.
What the research says
The 25 included trials span several decades and include a variety of treatments and PQ doses. Related to safety assessment, some trials
tested participants for G6PD activity. Other trials reported results based on their G6PD status, others did not test (or did not say
whether they did), and others tested and excluded people with G6PD deficiency.
There were no ideal community-level studies that would answer the question directly.
Five feeding trials withmultiple arms included three low-dose, threemedium-dose, and two high-dose comparisons, showing amarkedly
reduced proportion of people infectious who received PQ in trials with any events. Two trials using older malaria treatments and high
dose PQ had similar results.
The other trials focused on indirect measures of potential infectiousness of humans to mosquitoes. In these trials, PQ shortened the
period of potential infectiousness, with a lower prevalence and density of gametocytes up to day 8 after treatment. The effect was similar
at all PQ dose levels.
Few serious haemolytic events occurred in these trials, but PQ did affect non-serious haemoglobin measures, even at low doses.
What are the main results of the review?
A single low dose of PQ added to an artemisinin regimen for malaria reduces infectiousness to mosquitoes and is relatively safe for
most people.
PQ at WHO-recommended dose reduces infectiousness to mosquitoes on day 3-4 and day 8 with no evidence of harm. It is unclear
whether this reduction would materially reduce malaria transmission in communities.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low-dose primaquine (PQ) given with artemisinin combination treatment
Participants or population: adults and children with malaria being treated with artemisinin combinat ion treatment
Settings: Mali, Burkina Faso, The Gambia, Tanzania, Senegal
Intervention: single dose PQ dose 0.2 to 0.25 mg/ kg
Comparison: no PQ
Outcomes Number of participants
(trials)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
Risk with no PQ, with
artemisinin partner
Risk with single dose
PQ at 0.2 to 0.25 mg/
kg
Part icipants infect ious
at day 3-4
105
(3 RCTs)
RR 0.12
(0.02 to 0.88)
14 per 100 2 per 100
(0 to 13)
⊕⊕©©
LOW1
Due to imprecision
Low-dose PQ may re-
duce infect iousness
Part icipants infect ious
at day 8
243
(4 RCTs)
RR 0.34
(0.07 to 1.58)
4 per 100 1 per 100
(0 to 6)
⊕⊕©©
LOW1
Due to imprecision
Low-dose PQ may re-
duce infect iousness
Part icipants with game-
tocytes at day 3 to 4 by
PCR
414
(3 RCTs)
RR 1.02
(0.87 to 1.21)
52 per 100 53 per 100
(45 to 63)
⊕⊕⊕©
MODERATE2
Due to imprecision
Low-dose PQ probably
has lit t le or no ef fect on
gametocytes detected
by PCR at day 3 to 4
Part icipants with game-
tocytes at day 8 by PCR
532
(4 RCTs)
RR 0.52
(0.41 to 0.65)
47 per 100 25 per 100
(19 to 31)
⊕⊕⊕⊕
HIGH
Low-dose PQ reduces
gametocytes detected
by PCR at day 8
Part icipants with se-
vere haemolysis
752
(4 RCTs)
RR 0.98
(0.69 to 1.39)
13 per 100 13 per 100
(9 to 18)
⊕⊕⊕©
MODERATE2
Due to imprecision
Low-dose PQ probably
has lit t le or no ef fect on
severe haemolysis
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*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; PCR: polymerase chain react ion; RCT : randomised controlled trial; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 2 for imprecision: the CIs are wide; in addit ion, there is a large ef fect combined with a low number of events,
which creates further uncertainty around the point est imate.
2Downgraded by 1 for imprecision: the CIs are wide.
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B A C K G R O U N D
Description of the condition
Malaria is a febrile illness due to infectionwith thePlasmodiumpar-
asite, and is transmitted between humans via mosquitoes (Phillips
2017). Of the five Plasmodium species known to cause illness in
humans, Plasmodium falciparum is the most common, especially
in sub-Saharan Africa, and causes the majority of severe illnesses
and deaths (WHO 2016). The clinical illness develops due to the
presence of asexual stage parasites (merozoites and schizonts) in
the person’s bloodstream, but transmission to mosquitoes is via
sexual stage parasites (gametocytes), which develop from other
blood stages at some point after infection (Phillips 2017).
Artemisinin-based combination therapies (ACTs) are currently
recommended worldwide as the primary treatment for infection
with P. falciparum (WHO 2010). The artemisinin derivatives treat
the clinical illness by rapidly reducing the number of circulating
schizonts andmerozoites, which also reduces the potential for these
stages to develop into gametocytes for onward transmission. The
artemisinin derivatives have been shown to kill early developing
gametocytes, but they have nodirect effects onmature gametocytes
(Price 1996; Chotivanich 2006; Okell 2008a; Okell 2008b). The
partner drugs in ACTs (mefloquine, amodiaquine, piperaquine,
lumefantrine, and sulfadoxine-pyrimethamine) are schizonticides
with variable effects on gametocytes, and none adequately targets
mature gametocytes (Drakeley 2006; Barnes 2008). In untreated
infection, gametocytes can remain present for months as succes-
sive new generations are produced, and even following treatment
they may persist for several weeks (Smalley 1977; Eichner 2001;
Bousema 2010).
The mean circulation time of a mature P. falciparum gametocyte
in humans has been estimated by microscopy or polymerase chain
reaction (PCR) to be between 3.4 and 6.5 days (Smalley 1977;
Eichner 2001; Bousema 2010). The infectivity of a person de-
pends on the density of gametocytes in the bloodstream (Carter
1988; Bousema 2012). The percentage of bites on people that
result in mosquito infection ranges between 0.3% and 46%, al-
though most estimates are in the range of 1% to 10% (Graves
1988; Killeen 2006; Churcher 2013).
After uptake of a P. falciparum-infected blood-meal by the
mosquito, the haploid gametocytes mature into male and fe-
male gametes. When fertilized, diploid oocysts develop on the
mosquito’s stomachwall and subsequentlymature into sporozoites
that migrate to the salivary glands, ready to be released when bit-
ing the next host. The median number of oocysts formed in wild-
caught infected mosquitoes is two to three (Rosenberg 2008).
Each oocyst develops thousands of sporozoites, but only about
20% are thought to reach the mosquito salivary glands and fewer
than 25 sporozoites on average are ejected during mosquito blood-
feeding (Rosenberg 1990; Rosenberg 2008).
Description of the intervention
Primaquine (PQ) is the only drug in common use that is
known to kill mature P. falciparum gametocytes (Burgess 1961;
Pukrittayakamee 2004; Chotivanich 2006), and with the recent
emphasis on malaria elimination, there has been a renewed inter-
est and emerging literature on PQ’s potential value in reducing
malaria transmission (Eziefula 2012; White 2012; WHO 2012b;
White 2013). PQ is an 8-aminoquinoline (8AQ) whose pharma-
cokinetic mode of action is not well understood, but it is known to
be rapidly metabolized, with a half-life of six hours (White 1992).
PQ does not directly affectP. falciparum asexual stages which cause
the clinical illness (Arnold 1955; Pukrittayakamee 2004), and does
not appear to affect the early or maturing gametocytes (Bhasin
1984; White 2008). Consequently, a combination of PQ and an
artemisinin derivative (as part of ACT) would target all gameto-
cyte stages and have the greatest potential for reducing onward
transmission to mosquitoes (WHO 2012b; White 2013).
One of the constraints to widespread use of PQ is that the drug
is known to be a haemolytic trigger in people with glucose-6-
phosphate dehydrogenase (G6PD) deficiency. The deficiency is
X-linked and expressed in a wide variety of variants and levels of
G6PD deficit (Howes 2013). PQ can occasionally cause serious
haemolytic anaemia, haemoglobinaemia, and renal failure. The
effect depends on the degree of enzyme deficiency, the dose of
PQ, and the pattern of the exposure. These occasional, but clearly
serious, adverse effects have led to a reputation of being “unsafe”
(Ashley 2014). Although the haemolysis appears less likely at lower
dose, there have been few studies in G6PD-deficient people at low
doses of PQ (Olalekan 2017).
The WHO 2010 Guidelines for the Treatment of Malaria recom-
mended adding a single dose of PQ at 0.75 mg/kg to treatment for
uncomplicatedP. falciparummalaria in people who are notG6PD-
deficient with the goal of reducing transmission at the community
level (WHO 2010). However, since testing for G6PD deficiency
was rarely done and due to the concerns about the safety of this
single dose, the WHO convened a special expert review group in
2012 to reconsider this recommendation (WHO 2012a). The ex-
pert group concluded that:
• G6PD testing should be done more widely;
• countries already implementing single-dose PQ should
reduce the dose to 0.25 mg/kg in G6PD-deficient patients; and
• countries not currently implementing single-dose PQ but
which are targeting malaria elimination, or are threatened by
artemisinin resistance, should add 0.25 mg/kg PQ to treatment
for uncomplicated P. falciparum malaria (White 2012).
These conclusions were then incorporated into a revised WHO
recommendation in treatment guidelines (WHO 2012b) for 0.25
mg/kg PQ in the above circumstances, with the goal of reducing
transmissibility of treated P. falciparum infections (except in preg-
nant women, infants under six months of age, and women breast-
feeding infants under six months of age). A slightly revised policy
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was then included in an updated policy brief (WHO 2015a), and
in the third edition of the WHO Guidelines for the Treatment of
Malaria (WHO 2015b), which expanded the area of recommen-
dation to all “low transmission areas”; this was a strong recommen-
dation with low certainty evidence and it was stated that G6PD
deficiency testing was not required.
How the intervention might work
A single dose of PQ could contribute to reducing malaria trans-
mission through its effects on mature gametocytes, and it is rea-
sonable to assume that reducing the density and duration of ga-
metocytes in the blood of infected people (gametocytaemia) will
reduce the duration of potential infectiousness to mosquitoes at
the level of the individual (see Figure 1). However, any subsequent
effects on the number of mosquitoes infected from infected peo-
ple (infectiousness) or the number of new malaria infections in
the community (transmission) cannot be assumed and requires
estimation of these effects using reliable methods and some direct
evidence.
Figure 1. Review logic framework: the potential points in the Plasmodium parasite life cycle that could be
impacted by PQ and the outcomes used to measure impact. Abbreviations: AUC: area under the curve. EIR:
entomological inoculation rate; PQ: primaquine.
Infectiousness to mosquitoes can be measured directly by allowing
mosquitoes to feed on infected individuals (or their blood) who
have been treated with and without PQ (Killeen 2006; Bousema
2012; Dicko 2016; Gonçalves 2016a; Gonçalves 2016b; Okebe
2016; Lin 2017), or estimated indirectly by measuring the infec-
tion rates of wild-caught mosquitoes (Graves 1990; Lines 1991).
Community-level transmission can be measured through large
cluster-randomized trials, or less reliably through controlled be-
fore-and-after studies. Within any community there are people
who are carriers of P. falciparum gametocytes but who do not seek
treatment (Bousema 2011). This is most apparent in areas of high
endemicity, where much of the adult population has acquired im-
munity, so low-level parasitaemias do not produce symptoms. This
reservoir of gametocytes in untreated adults will continue to facili-
tate community level transmission and may dilute any possible ef-
fect of PQ in moderate to high level transmission settings. Indeed,
these dilutional effects may even be important in low transmission
settings (Ouédraogo 2009; Bousema 2014; Stone 2015).
Recently, with the move toward a target of elimination, some pol-
icy makers are considering mass treatment strategies to reduce
transmission or contain outbreaks once transmission is reduced to
low levels (von Seidlein 2003; Sturrock 2013). In this situation, it
seems more likely that a higher proportion of the population with
gametocyteswill be detected or treated, or both, and that this could
be effective in reducing or interrupting transmission. This policy
is being considered in countries with lower intensity transmission,
or on islands or at the northern and southern fringes of malaria
distribution, or both (GMAP 2008; Mendis 2009). Effective an-
timalarial drugs are likely to play a large role in this new strategy.
One question in this effort is whether there is a role for PQ given
in addition to curative antimalarial drugs, including ACTs, to fur-
ther reduce the infection transmissibility (White 2008). Recent
modelling has questioned the value of the additional impact of
PQ to mass drug administration (MDA) (Johnston 2014; WHO
2015c).
The transmission blocking potential of PQhas also been suggested
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as a strategy to reduce the spread of artemisinin-resistant parasites
in Southeast Asia (Breman 2012). While it is certainly important
to urgently expand access to treatment for persons with such para-
sites, PQ does not act on asexual stages, which would still produce
gametocytes as usual in resistant infections. Thus it is not clear
how this would work, and it may actually be counterproductive
(Hastings 2006).
Why it is important to do this review
PQ could play a role in P. falciparummalaria control, particularly
malaria elimination and possibly eradication. Defining the strate-
gies in which PQ will be most effective depends on getting the
details right on dose, timing, and the situations in which it is used.
It has become clear that ACTs have differing effects on gametocyte
carriage following treatment, even without PQ (WWARN 2016).
Therefore the effectiveness may vary considerably, but adverse ef-
fects - particularly the haemolytic effects of PQ - occur indepen-
dently of effectiveness. That is, even if used in situations when it
is largely ineffective, the rate of adverse reactions will be constant.
Since it is the haemolytic effects that are often foremost in the
minds of government health staff, building a case for the use of the
drug depends on convincing evidence of its value in malaria con-
trol, including in implementation of WHO recommendations.
O B J E C T I V E S
1. To summarize any reliable direct research evidence that com-
munity programmes of single low dose PQ reduce malaria trans-
mission.
2. For currently recommended artemisinin combination treat-
ments for P. falciparum infections, to summarize reliable research
evidence on the effect of adding a single dose of PG/8AQ on infec-
tiousness of infected people to mosquitoes, gametocytaemia and
any evidence of haemolysis, stratified by:
• the current standard recommended dose of 0.25 mg/kg;
• previously recommended doses (up to 0.75 mg/kg).
3. To repeat the analysis of effects of single dose PQ, stratified
by dose, for non-artemisinin based combination treatments for P.
falciparum infections.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) or quasi-RCTs including in-
dividual- or cluster-RCTs. Cluster-RCTs must have had at least
two clusters per arm.
Types of participants
Adults or children with P. falciparum infection or a mixed infec-
tion of P. falciparum and other Plasmodium species. For individ-
ual RCTs, eligible studies must have diagnosed patients by blood
slide, rapid diagnostic test, or other valid molecular method; for
cluster-RCTs, diagnosis could have been by clinical judgment if
that was standard in the trial area at the time of the trial.
Types of interventions
Intervention
A single dose or short course (up to seven days) of PQ (at doses
of 0.2 mg/kg per day or above) or other 8AQ added to malaria
treatment(s).
Control
Identical treatment for malaria not including PQ/8AQ (or substi-
tuting placebo for PQ/8AQ); or using a different 8AQ with same
malaria treatment, or using different dose of PQ/8AQ with same
malaria treatment(s).
Types of outcome measures
Transmission
Any measure of community burden or incidence of malaria (en-
tomological inoculation rate (EIR) measured in mosquitoes, in-
cidence of new malaria infections, or prevalence of malaria infec-
tion).
Infectiousness
• Number of participants infectious (leading to infection
with oocysts or sporozoites in at least one mosquito fed on them
or their blood) at day 3-5 and day 8.
• Proportion of mosquitoes infected by direct or membrane
feeding on blood of participants at day 3-5 and day 8.
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Potential infectiousness
• Number of participants with gametocytes detected by PCR
on day 3-4 and day 8.
• Number of participants with gametocyte detected by
microscopy on day 3-4 and day 8.
Other measures of gametocytes including gametocyte clearance
time (time to disappearance of gametocytes from the blood) and
area under the curve of gametocyte density over time where re-
ported.
Adverse effects
• Serious adverse events leading to hospital admission or
death.
• Participants with severe haemolysis as defined by the trial
authors. It was defined as drop of ≥ 25% (Dicko 2016;
Mwaiswelo 2016), ≥ 2 g (Gonçalves 2016b), or ≥ 2 g of
haemoglobin (Tine 2017) over the course of follow-up.
We also describe maximum or average absolute or percent change
in haemoglobin or packed cell volume (PCV) when this is re-
ported.
Figure 1 provides an outline of transmission of malaria to help
clarify the outcomes.
Search methods for identification of studies
We attempted to identify all relevant trials, regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
Databases
We searched the following databases up to 21 July 2017 us-
ing the search terms and strategy described in Appendix 1: the
Cochrane Infectious Diseases Group Specialized Register; the
Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library (Issue 1, 2017); MEDLINE
(PubMed; 1966 to 21 July 2017); Embase (OVID; 1980 to 21
July 2017); and LILACS (BIREME, 1982 to 21 July 2017).
Also, we checked ClinicalTrials.gov (https://clinicaltrials.gov/ct2/
home) and the WHO International Clinical Trials Registry Plat-
form (ICTRP); http://www.who.int/ictrp/en/; both accessed 21
July 2017) using ‘malaria*’, ‘falciparum’, ‘primaquine’, ‘8-amino-
quinoline’, and eight other individual 8AQ names as search terms.
Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: theMIM Pan-African Malaria Conferences and the Amer-
ican Society of Tropical Medicine and Hygiene (ASTMH) to De-
cember 2009.
Searching other resources
Researchers and organizations
Wecontacted researcherswhowere authors of some of the included
and in-progress trials, other trial authors, and other experts in the
field of malaria chemotherapy.
Reference lists
We checked the reference lists of all studies identified by the above
methods.
Data collection and analysis
Selection of studies
Two review authors (PMG and HG) independently screened all
citations and abstracts identified by the search strategy, including
ongoing studies, for potentially eligible studies. We independently
assessed full reports of potentially eligible studies for inclusion in
the review. Notably, we did not contact any trial authors for clar-
ification regarding inclusion (although we later contacted several
about trial details) because it was clear whether trials were or were
not eligible for inclusion. We used translations of eight papers
published in Chinese to assess eligibility. We resolved differences
of opinion by discussion with PG. We listed all studies excluded
after full-text assessment, and their reasons for exclusion, in the
‘Characteristics of excluded studies’ table. We have illustrated the
study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (PMG and HG) independently extracted the
following information for each trial using a data extraction form.
Trial characteristics
• Design (RCT or quasi-RCT, type of randomization).
• Dates and duration of trial.
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Participant characteristics
• Number of participants.
• Age and sex of participants.
• Proportion with G6PD deficiency.
• Proportion with gametocytes at onset of trial.
• Inclusion criteria.
• Exclusion criteria.
Intervention characteristics
• Type of drug, dose, and schedule.
Presented outcomes
• Description of outcomes presented in the papers.
Other
• Location of trial, setting, and source of funding.
• Local endemicity of malaria.
Outcomes data
For each trial, two review authors (PMG and HG) extracted data
on the trial outcomes eligible for inclusion in this review for the
PQ and non-PQ groups. We extracted the number of participants
randomized and the numbers analysed in each treatment group
for each outcome. For dichotomous data outcomes (proportion
of participants infectious to mosquitoes, proportion of partici-
pants with gametocytes, proportion of mosquitoes infected), we
extracted the number of participants experiencing the event of in-
terest and the total number of participants or mosquitoes in each
treatment arm of each trial. We noted details on the method of
determining parasite presence and density, for example light mi-
croscopy (if so, the method of staining and number of fields ex-
amined), PCR, or other methods.
For G6PD deficiency, we noted the sex of the carrier (if stated) and
the method used to determine G6PD deficiency, either phenotyp-
ically (by enzyme function) or genotypically (PCR). We adopted
the definition of ‘deficient’ used in the trials that assessed this out-
come. We extracted adverse event data for each individual type
of event wherever possible. Where adverse events were reported
separately for more than one dose (for short-course regimens),
we attempted to record the average number of people reporting
each adverse event for each dose. If trials reported the occurrence
of adverse events at more than one time point following a single
dose, but did not record the total number of people reporting each
event, we attempted to record the events occurring in the first time
period.
In cases of disagreement, we double checked the data and we
reached consensus through discussion between all review authors.
Assessment of risk of bias in included studies
Two review authors (PMG and HG) independently assessed the
risk of bias of the included trials as recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
For each included trial, we assigned a judgement of low, unclear, or
high risk of bias for the following components: random sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessors, incomplete outcome
data, selective outcome reporting, and other biases.
For sequence generation and allocation concealment, we described
the methods used, if given. For blinding, we described who was
blinded and the blinding method. For incomplete outcome data,
we reported the percentage and proportion of loss to follow-up
(the number of participants for whom outcomes are not measured
of the number randomized), if given. For selective outcome re-
porting, we stated any discrepancies between the methods and the
results in terms of the outcomes measured and the outcomes re-
ported; we also stated if we knew that an outcome was measured
but was not reported in the publication. For other biases we de-
scribed any other trial features that could have affected the trial’s
results (for example, whether a trial was stopped early or if no sam-
ple size calculation was included). We resolved any disagreements
through discussion.
We reported the results of the risk of bias assessment in a ‘Risk
of bias’ table and displayed them in a ‘Risk of bias’ summary and
‘Risk of bias’ graph (Figure 2; Figure 3).
10Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
trial.
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Figure 3. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
Measures of treatment effect
We analysed the data using Review Manager 5 (RevMan 5)
(RevMan 2014). For dichotomous data, we estimated the risk ra-
tio (RR) and used the Mantel-Haenszel method with fixed-effect,
or with random-effects if there was heterogeneity. For continuous
data, we estimated the mean difference (MD). All results are pre-
sented with 95% confidence intervals (CIs). We reported results
only for days after the first day of PQ treatment, which, in some
trials, was later than the beginning of primary treatment.
When one trial contained more than one comparison with the
same placebo group and there was an analysis total or subtotal, we
divided the placebo group participants between the comparisons
to avoid double-counting participants and falsely overestimating
the precision.
Unit of analysis issues
All the included trials were individually randomized and analysed
accordingly.
Dealing with missing data
Where data were missing from the trials or details were unclear,
we attempted to contact the trial authors. We used complete case
analysis (that is, excluding dropouts rather than ‘intention to treat’
analysis) for trials with missing data.
Assessment of heterogeneity
We assessed heterogeneity between the trials by examining the
forest plots to check for overlapping CIs, using the Chi2 test for
heterogeneity with a 10% level of significance and the I2 statistic
with a value of 50% to represent moderate levels of heterogeneity.
Assessment of reporting biases
Therewere insufficient trials (less than10)within each comparison
to assess the likelihood of small trial effects, such as publication
bias, by examining a funnel plot for asymmetry (Higgins 2011).
Data synthesis
We prespecified subgroups for analysis by artemisinin or non-
artemisinin basedmalaria treatment regimens anddescribedwhich
antimalarial drug was used for each comparison in a footnote. We
prespecified strata by PQ dose category: low (0.2 to 0.25 mg/kg),
medium (0.4 to 0.5 mg/kg), and high (0.75 mg/kg dose); and
grouped the 8AQ drugs as PQ and other. Throughout this review,
to enable standardization between trials, we designated the first
day of any treatment drug as day 1 rather than day 0 as reported
in some trials.
Where not stated as mg/kg, we reported the PQ dose as the adult
dose with the equivalent dose reported as mg/kg; most trials stated
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that the dose was adjusted for children and if not stated, we made
this assumption.
When there was no statistically significant heterogeneity between
trials, we applied the fixed-effect meta-analysis model. When we
observed statistically significant heterogeneity within groups that
could not be explained by subgroup or sensitivity analyses, we
used a random-effects meta-analysis model. When we determined
substantial heterogeneity from the assessments of heterogeneity
(I² statistic value > 50%), we did not undertake meta-analysis but
instead presented a Forest plot with the pooled effect suppressed.
Certainty of the evidence
We assessed the certainty of the evidence using the GRADE ap-
proach (Guyatt 2011). We rated each primary outcome as de-
scribed by Balshem 2011 as follows.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high certainty evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect; a dose
response effect; and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect
if no effect was observed (Balshem 2011). We summarized our
findings in a ‘Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
In our protocol, we stated we would investigate heterogeneity in
relation to drug resistance pattern, the parasite density before treat-
ment, and the local endemicity of malaria. However, we identified
too few trials for inclusion to perform these analyses.
Sensitivity analysis
There were insufficient trials to conduct a sensitivity analysis to
investigate the robustness of the results to the quality (risk of bias)
components.
R E S U L T S
Description of studies
Results of the search
In the last published version of this review, Graves 2015, we in-
cluded a total of 18 trials. There was one instance of duplicate
reports of the same trial in different languages (Chen 1994). Trials
frequently included arms with distinct comparisons of different
malaria treatment partner drugs, doses, or schedules; thus the 18
previously included trials had 30 arms.
For this update, a literature search update to 21 July 2017 iden-
tified 53 new records. Four new publications (Eziefula 2013;
Eziefula 2014; Pett 2014; Chang 2016) were additional reports
from a previously included trial (Eziefula 2013). Of the remainder,
10 records were selected for full text review and we excluded 39
records.
Ten new publications described seven new trials published since
the last revision (Dicko 2016;Gonçalves 2016a;Gonçalves 2016b;
Mwaiswelo 2016; Okebe 2016; Lin 2017; Tine 2017). The
Goncalves study is regarded as two trials because the two phases
had different inclusion criteria (Gonçalves 2016a; Gonçalves
2016b).
The seven new trials included a total of 16 separate comparison
arms. Therefore, this update now includes 25 trials which had
46 total arms (Table 1). There were 14 trials with artemisinin-
only arms (seven with one arm, two with two arms, three with
three arms, one with four arms, and one with five arms). There
were nine trials with non-artemisinin only arms (six with one arm
and three with two arms). Two trials had both artemisinin and
non-artemisinin arms. Three artemisinin arms in two trials were
excluded because they used doses lower than 0.2 mg/kg (Eziefula
2013; Dicko 2016), leaving 43 included arms in the 25 trials.
We updated Figure 4, which shows the flow diagram of included
studies, accordingly. We still could not locate three articles that
were cited in the ‘Studies awaiting classification’ section in the
previous and this version.
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Figure 4. Study flow diagram
Included studies
The 25 included trials comprised 24 individually randomized
RCTs and one quasi-RCT which used alternate allocation (Arango
2012). Two trials compared PQ and bulaquine (BQ), while 23
trials compared PQ versus no PQ. One trial of PQ, Khoo 1981,
did not distinguish between participants given a short or long
course of PQ and therefore no outcomes are included in this re-
view. Two trials did not include any gametocyte outcomes (Wang
2006; Mwaiswelo 2016).
Trials reporting community transmission
No cluster trials examining malaria transmission intensity in com-
munities met the inclusion criteria.
Trials reporting infectiousness
Five trials reported on infectiousness of participants to mosquitoes
by direct or membrane feeding of people given ACTs compared
to ACT+PQ (Dicko 2016; Gonçalves 2016a; Gonçalves 2016b;
Okebe 2016; Lin 2017). These trials were conducted in Burkina
Faso (partner drugAL),Mali (DHAP), TheGambia (DHAP), and
Cambodia (DHAP), respectively. In addition, Mwaiswelo 2016
planned to test infectivity in Tanzania with AL as partner drug,
but no infectiousness or gametocyte outcomes were reported.
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For direct measures of infectiousness with non-ACT partner
drugs, two small trials in China evaluated the infectiousness to
mosquitoes of people treated with mefloquine (MQ) compared to
MQ+PQ (Chen 1993a; Chen 1994).
Trials reporting potential infectiousness
Twenty-two trials examined the impact of PQ or 8AQ on various
measures of potential infectiousness, such as gametocyte preva-
lence or density over time in participants after treatment, ga-
metocyte clearance time, or gametocyte circulation time. Three
trials with artemisinin partners assessed gametocyte prevalence
by PCR only (El-Sayed 2007; Dicko 2016; Okebe 2016). Five
trials reported both microscopy and PCR gametocyte detection
(Shekalaghe 2007; Eziefula 2013; Gonçalves 2016a; Gonçalves
2016b; Lin 2017), and the others with either artemisinin or
non-artemsisinin partners reported gametocyte prevalence by mi-
croscopy only.
Five trials with artemisinin partners reported area under curve
(AUC) or log(10)AUC as a summary combined measure of game-
tocyte prevalence and density over time, using PCR estimates of
density (Shekalaghe 2007; Eziefula 2013; Dicko 2016; Gonçalves
2016b; Tine 2017).
Trials reporting adverse effects
Eleven trials reported adverse effects quantitatively, with 44 dif-
ferent types of effects reported. Nine trials included anaemia out-
comes (El-Sayed 2007; Shekalaghe 2007; Eziefula 2013; Dicko
2016;Gonçalves 2016a;Mwaiswelo 2016;Okebe 2016; Lin 2017;
Tine 2017), and two reported only non haemolytic effects (Wang
2006; Sutanto 2013) (Analysis 1.9 to Analysis 1.18, and Analysis
3.6).
Participants
Place of recruitment
Participants were usually people attending health clinics for treat-
ment, but Dicko 2016 actively recruited participants from the
community for a second phase of the trial when insufficient infec-
tive participants were found in phase 1.
Age
Four trials did not state the participants’ ages (Khoo 1981; Chen
1993a; Chen 1994; El-Sayed 2007), and five trials included chil-
dren only: Singhasivanon 1994 (five to 12 years); Shekalaghe 2007
(three to 15 years); Eziefula 2013 (one to 10 years); Gonçalves
2016a and Gonçalves 2016b (two to 15 years). Nine trials used
a wide age range of children and adults: Wang 2006 (six to 60
years); Vásquez 2009 (≥ one year); Smithuis 2010 (> six months);
Arango 2012 (one to 75 years); Kolaczinski 2012 (three to 70
years); Sutanto 2013 (≥ five years);Mwaiswelo 2016 (≥ one year);
Okebe 2016 (> one year) and Dicko 2016 (five to 50 years). The
remaining seven trials included teenagers and adults only: Gogtay
2004 (> 18 years); Kamtekar 2004 (> 16 years); Lin 2017 (18 to
65 years); Tine 2017 (18 to 74 years); Pukrittayakamee 2004 (15
to 62 years); Gogtay 2006 (> 16 years); and Lederman 2006 (≥
15 years). See the ‘Characteristics of included studies’ section.
G6PD deficiency
For G6PD deficiency, two trials did not screen participants
(Kamtekar 2004; Smithuis 2010), three trials screened and in-
cluded all participants (Shekalaghe 2007; Mwaiswelo 2016; Tine
2017), one trial included only G6PD-deficient participants (Khoo
1981), 11 trials included only non-severely deficient participants
(Gogtay 2004; Pukrittayakamee 2004; Gogtay 2006; Lederman
2006; Sutanto 2013; Eziefula 2013; Dicko 2016; Gonçalves
2016a; Gonçalves 2016b; Okebe 2016; Lin 2017), and the re-
maining eight studies made no comment (Chen 1993a; Chen
1994; Singhasivanon 1994; Wang 2006; El-Sayed 2007; Vásquez
2009; Arango 2012; Kolaczinski 2012); see Table 1.
Baseline infectiousness
In Dicko 2016, baseline infectiousness (proportion of persons in-
fectious) prior to treatment in both groups combined was 58/73
(79%), with no obvious imbalance between the treatment groups.
In Goncalves phase 1, no baseline infectiousness was measured
(Gonçalves 2016a); in phase 2, 79 of the 149 participants were
tested for infectiousness at baseline, and 30/79 (38%) were in-
fectious (all groups combined) (Gonçalves 2016b). In Lin 2017,
baseline infectiousness of participants reported on day 0 appeared
unbalanced: DHAP 6/51 (12%); DHAP+PQ 1/51 (2%). This is
assumed to reflect selection bias or a failure of randomization.
Interventions
Background drug
Sixteen trials (31 treatment arms) evaluated PQ given along-
side artemisinin-based treatments: artesunate (AS) (two trials, two
arms), AS+SP (two trials, two arms), AS+MQ (three trials, four
arms), AS+AQ (two trials, two arms), artemether-lumefantrine
(AL) (five trials, ten arms) and dihydroxyartemisinin-piperaquine
(DHAP) (six trials, 11 arms). Two trials included two and one
arms, respectively, with doses too low (< 0.2mg/kg) to be included
here (Eziefula 2013; Dicko 2016). One trial, Tine 2017, included
arms with AL, DHAP and ASAQ, but they were combined in the
paper and here for analysis.
Eleven trials (15 treatment arms) evaluatedPQorBQ, given along-
side non-artemisinin-based treatments. Nine trials (13 treatment
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arms) evaluated PQ given alongside the following: chloroquine
alone (CQ) (three trials, four arms), CQ alone or CQ+SP (one
trial, one arm), SP (one trial, one arm), mefloquine (MQ) (two
trials, two arms),MQ+SP (one trial, one arm), quinine (QN) (two
trials, three arms), and amodiaquine (AQ)+SP (one trial, one arm).
Two trials (two treatment arms) evaluated BQ given alongside the
following: QN (one trial, one arm) and QN plus doxycycline (one
trial, one arm).
Dose
Sixteen trials included the previous standard dose of 0.75 mg/kg
PQ per day (adult dose 45 mg/day); see Table 1. The trials using
different doses were as follows.
• Khoo 1981: adult dose of 25 mg or approximately 0.42
mg/kg/day.
• Kolaczinski 2012: (two arms) 0.5 mg/kg or adult dose 30
mg/day.
• Pukrittayakamee 2004: the trial with QN had two arms,
one with 0.25 mg/kg and the other 0.5 mg/kg per day (adult
dose 15 mg or 30 mg per day, respectively); the comparison with
AS used 0.5 mg/kg per day (adult dose 30 mg per day).
• Wang 2006: adult dose of 22.5 mg or approximately 0.38
mg/kg per day.
• Eziefula 2013: 0.1 (not included in this review), 0.4 and
0.75 mg/kg.
• Dicko 2016: 0.125 (not included in this review) and 0.5
mg/kg in phase 1 and 0.0625 (not included in this review) and
0.25 mg/kg in phase 2.
• Gonçalves 2016a: 0.2 and 0.4 mg/kg.
• Gonçalves 2016b: 0.2 and 0.4 mg/kg.
• Okebe 2016: 0.2, 0.4 and 0.75 mg/kg.
• Mwaiswelo 2016: 0.25 mg/kg.
• Tine 2017: 0.25 mg/kg.
This review reports the results for clinically important doses only:
0.2 to 0.25 mg/kg, 0.4 to 0.5 mg/kg, and 0.75 mg/kg.
Schedule
We regarded the first day of any treatment as day 1. Most trials
used a single dose of PQ given on the following days.
• Day 1: Chen 1993a; Chen 1994; Singhasivanon 1994;
Lederman 2006 (one of two comparisons); Smithuis 2010 (five
arms); Kolaczinski 2012 (one of two arms); Dicko 2016;
Mwaiswelo 2016; Tine 2017 (three arms).
• Day 2: Arango 2012 (two arms).
• Day 3: Lederman 2006 (one of two arms); Vásquez 2009;
Kolaczinski 2012 (one of two arms); Eziefula 2013; Sutanto
2013; Gonçalves 2016a (two arms); Gonçalves 2016b (two
arms); Okebe 2016 (three arms); Lin 2017.
• Day 4: Gogtay 2004; Kamtekar 2004 (one of two arms);
Gogtay 2006; El-Sayed 2007; Shekalaghe 2007.
• Day 8: Kamtekar 2004 (one of two arms).
Three trials used a longer course of PQ.
• Three days: Khoo 1981.
• Five days: Wang 2006.
• Seven days: Pukrittayakamee 2004 (three arms).
Length of follow-up
The maximum time of follow-up varied between trials. It was re-
stricted here to eight days after treatment to enablemaximumcom-
parison between trials (some of which terminated at this point).
Therefore, not all results from Kamtekar 2004 could be included
since PQ was given on day 8 in one arm.
Prevalence of gametocytes at start of trial
The trials varied in inclusion criteria and hence in how representa-
tive they were of the gametocyte prevalence of the general or clinic
population. Five trials included only people with microscopically
detected gametocytes at onset (Chen 1993a; Chen 1994; Gogtay
2004; Gogtay 2006; Dicko 2016). In Kamtekar 2004 over 90%
of participants were gametocyte positive by microscopy, but this
variable was reported as “within 3 days” rather than on day 1.
The Gonçalves 2016b trial had the next highest prevalence by
microscopy, of 69%. The five arms of the Smithuis 2010 trial
showed moderately high gametocyte prevalence (microscopy) be-
tween 29% and 38% depending on the arm. Trials with initial ga-
metocyte prevalence between 15% and 27% by microscopy were:
Pukrittayakamee 2004; Shekalaghe 2007; Vásquez 2009; Arango
2012; Kolaczinski 2012; Eziefula 2013; Gonçalves 2016a; and
Sutanto 2013. The remaining three trials had low (< 15%) game-
tocyte prevalence by microscopy at onset (Mwaiswelo 2016; Lin
2017; Tine 2017).
Two trials reported PCR prevalence only: El-Sayed 2007, with
10.5% and Okebe 2016, with 48%. Four trials did not report the
prevalence of gametocytes at onset (Khoo 1981; Singhasivanon
1994; Lederman 2006; Wang 2006).
The details of the trial locations, malaria treatments, gametocyte
prevalence at onset, 8-AQ doses, and schedules are in Table 1.
Outcomes
Transmission
For malaria transmission intensity (prevalence, incidence or EIR),
we found no community cluster-RCTs measuring these outcomes
that met inclusion criteria.
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Infectiousness
Infectiousness includes two components: proportion of partici-
pants infectious, and proportion of mosquitoes infected. Six trials
intended tomeasure infectiousness with artemisinin partner drugs
(DHAP, ASAQ, or AL) (Gonçalves 2016a; Gonçalves 2016b;
Dicko 2016; Mwaiswelo 2016; Okebe 2016; Lin 2017) and five
(all except Mwaiswelo 2016) provided such data. Two trials mea-
sured infectiousness with non-artemisinin drugs (in both cases
MQ)with and without PQ (Chen 1993a; Chen 1994). Results are
reported here for two time points after commencement of treat-
ment. The first day of treatment is day 1. The goal was reporting
at day 4 and 8, but day 4 was varied to day 3 or 5 for some trials.
Potential infectiousness
All other trials (exceptWang 2006 andMwaiswelo 2016) reported
potential infectiousness: that is, the effects of PQ on gametocyte
prevalence, density, or clearance time, or all three outcomes using
either microscopy or PCR. The same time points are reported as
for infectiousness (day 3, 4, or 5, and day 8).
Nine trials reported gametocyte clearance time (Singhasivanon
1994; Pukrittayakamee 2004; Shekalaghe 2007; Smithuis 2010;
Eziefula 2013; Dicko 2016; Gonçalves 2016b; Lin 2017; Tine
2017). Four of these also reported a summary measure of poten-
tial infectiousness using area under the curve (AUC) of gameto-
cyte density over time (Pukrittayakamee 2004; Smithuis 2010;
Gonçalves 2016b; Lin 2017).
Wang 2006 andMwaiswelo 2016 reported only asexual stage out-
comes and Khoo 1981 reported data that could not be used as the
length of PQ course for each participant was not clear.
Excluded studies
We have listed the reasons for exclusion of 48 trials in the
‘Characteristics of excluded studies’ section. Some additional de-
tails of these trials and reasons for exclusion are expanded in a
previous edition of this review (Graves 2014).
We sought publications for Chinese trials cited in White 2012
and White 2013 and by personal communication from Professor
Li Guo Qiao. We were unable to locate two (Chen 1993b; Li
2006); the others were translated where required. We excluded
the following studies on the basis of no appropriate comparison
(either all groups got PQ or there was no comparator group with
same dose of malaria treatment drug but no PQ): (Che 1987;
Yang 1989; Che 1990; Huang 1996; Lin 2004; Sun 2011) or
lack of randomization (Cai 1985; Huang 1993). Three other trials
of artemether with and without PQ in Africa were stated to be
randomized (Huang 2001; Li 2007; Li 2010), but we excluded
them due to the late administration of PQ (after five to seven days
of artemether) and lack of gametocyte outcomes.
Risk of bias in included studies
The ‘Risk of bias’ assessment for each of the 25 included trials is
shown in Figure 2 with a summary by component in Figure 3.
There was low risk of bias in 50% or more of trials for random se-
quence generation, allocation concealment, incomplete outcome
data, selective reporting, and other bias. High risk of bias was
present in less than 20% of the trials for these components. The
trials were weakest on blinding, with low risk of bias in less than
25% for blinding of participants and personnel, and less than 50%
of trials for blinding of outcome assessment. The highest risk of
bias (30% of trials) was for blinding of participants and personnel.
A relatively high proportion of trials (particularly older trials) did
not report sufficient information to clarify the risk of bias, espe-
cially for blinding and allocation concealment (≥ 30% of trials).
Pukrittayakamee 2004 excluded G6PD-deficient people from the
PQ group post-randomization. We had no reason to suppose it
biased the primary outcomes but it could have affected assessment
of adverse effects.
Effects of interventions
See: Summary of findings for the main comparison Single dose
primaquine at 0.2 to 0.25 mg/kg compared to no primaquine,
with artemisinin partner, for reducing P. falciparum transmission;
Summary of findings 2 Single dose primaquine at 0.4 to 0.5
mg/kg compared to no primaquine, with artemisinin partner,
for reducing P. falciparum transmission; Summary of findings
3 Single dose primaquine at 0.75 mg/kg compared to no
primaquine, with artemisinin partner, for reducing P. falciparum
transmission; Summary of findings 4 Single dose primaquine
at 0.4 to 0.5 mg/kg compared to no primaquine, with non-
artemisinin partner, for reducing P. falciparum transmission;
Summary of findings 5 Single dose primaquine at 0.75 mg/kg
compared to no primaquine, with non-artemisinin partner, for
reducing P. falciparum transmission
We subgrouped the data by whether or not the malaria treatment
was artemisinin-based, and by the gametocyte detection method.
We included only one measure of gametocyte prevalence by PCR
data if two different methods of PCR were reported, to avoid
duplicate reporting of the same participants (Gonçalves 2016b).
Results were stratified by two time points of follow-up, with the
exact day depending onwhat was reported. The goal was reporting
at day 4 and 8, but this was varied to day 3 or 5 and day 8 in some
trials. Results at these time points were included only if they were
after the administration of PQ. For day 3 outcomes, we excluded
Sutanto 2013 since PQ was given on that day. We excluded the
QN comparison of Kamtekar 2004 because PQ was not given
until day 8, but included all other trials with gametocyte outcomes
at day 8 (all trials except Khoo 1981, Pukrittayakamee 2004, and
Wang 2006).
Where reported, summary estimates of effects on gametocyte clear-
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ance time over the whole period of follow-up are reported.
The day on which PQ was given varied, and is presented for each
trial in Table 1 and in the footnotes to each analysis.
Results on infections acquired bymosquitoes are reported in tables
only because wewere not able to account for the bias due to varying
numbers of mosquitoes dissected per individual.
1. PQ as part of artemisinin-based treatment
regimens
Follow-up at day 3 or 4
Infectiousness of people to mosquitoes
Four trials assessed proportion of participants infectious to
mosquitoes on day 3 or 4 after first treatment on day 1. Results
were stratified by dose. Only one trial out of three in the low dose
(0.2 to 0.25 mg/kg) group had any events (infectious people) at
day 3-4 (Analysis 1.1). The proportion of people infectious to
mosquitoes was reduced by 88% (95% CI 12% to 98%, 105 par-
ticipants). In the moderate dose group, again only one trial had
any events. The proportion of people infectious was reduced by
87% (95% CI 6% to 98%, 129 participants). At the high dose of
0.75 mg/kg (one trial), the reduction in one trial was 80% but the
95% CI was very wide and overlapped 100% (2% to 168%, 51
participants).
Infections acquired by mosquitoes
Results were also expressed as the proportion of mosquitoes in-
fected. At baseline, before treatment with the low dose, the groups
were not well matched in one trial (Dicko 2016), with 29% more
mosquitoes infected in the PQ group (Table 2).With the low dose
and themoderate dose, on day 3 or 4, there was a slight decrease in
the proportion ofmosquitoes infected (Table 3) with data available
for only one trial out of three in each of the low- and moderate-
dose groups. In the 0.75 mg/kg dose group, the one trial showed
a slight increase in percentage of mosquitoes infected in the group
without PQ.
Gametocyte prevalence by PCR
At day 3 or 4 after treatment, there was no effect at any dose
on the proportion of persons with gametocytes detected by PCR
(Analysis 1.2). The risk ratios (RRs) (fixed effect) were 1.02 (95%
CI 0.87 to 1.21; 3 trials, 414 participants) for low dose; 1.09 (95%
CI 0.93 to 1.28; 3 trials, 418 participants) for moderate dose, and
0.92 (95% CI 0.75 to 1.13; 3 trials, 394 participants) for high
dose.
Gametocyte prevalence by microscopy
At day 3 or 4 after treatment, there was no reduction in proportion
of persons with gametocytes detected by microscopy for the low
and moderate doses (Analysis 1.3). The RRs were 0.73 (95% CI
0.21 to 2.50; 3 trials, 490 participants) for low dose, and 0.86
(95% CI 0.33 to 2.25; 2 trials, 225 participants) for moderate
dose. Due to heterogeneity, a random effects RR was estimated.
At the high dose, reduction of 58% was observed (RR 0.42, 95%
CI 0.20 to 0.85; 3 trials, 248 participants).
Follow-up at day 8
Infectiousness of people to mosquitoes
Four trials assessed proportion of participants infectious on day 8
after first treatment on day 1. Results were stratified by dose. Three
trials out of four using a low dose had events (infectious people)
at day 8 (Analysis 1.4). The proportion of people infectious to
mosquitoes was not significantly reduced at this time point (RR
0.34, 95%CI 0.07 to 1.58; 4 trials, 243 participants). In themod-
erate dose group, three of the four trials had any events. The reduc-
tion in proportion of people infectious was similar to the low dose
group (RR 0.33, 0.07 to 1.57; 4 trials, 246 participants). At the
high 0.75 mg/kg dose there were two trials, both with infectious
events in the non-PQ group (RR 0.18, 95% CI 0.02 to 1.41; 2
trials, 181 participants). Thus the reduction in infectiousness was
large but the 95% CI was very wide and overlapped one.
Infections acquired by mosquitoes
With the low and moderate dose, data on the proportion of
mosquitoes infected were available for three out of four trials in
each dose group (Table 4). One trial of the four in the low dose
group had 29%moremosquitoes infected in the PQ than the non-
PQ group (arising from one infectious individual). Otherwise,
there was very little difference between PQ and no-PQ groups in
the proportion of mosquitoes infected at day 8 in either the mod-
erate dose group (four trials) or the high dose group (two trials).
Gametocyte prevalence by PCR
At day 8 after first treatment, reductions were observed in the
proportionof personswith gametocytes detected byPCR (Analysis
1.5). The RRs (fixed effects) were 0.52 (95% CI 0.41 to 0.65; 4
trials, 532 participants) for low dose; 0.37 (95% CI 0.28 to 0.48;
4 trials, 758 participants) for moderate dose, and 0.31 (0.23 to
0.43; 5 trials, 793 participants) for high dose.
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Gametocyte prevalence by microscopy
At day 8 after treatment, there was also a reduction in the pro-
portion of people with gametocytes detected by microscopy for
all dose groups (Analysis 1.6). The RRs (fixed effects) were 0.35
(95% CI 0.16 to 0.78; 3 trials, 491 participants) for low dose;
0.25 (95% CI 0.08 to 0.75; 2 trials, 225 participants for moderate
dose, and 0.27 (95% CI 0.19 to 0.37; 6 trials (10 arms), 1433
participants) for high dose. There was moderate heterogeneity at
the high dose, but not at low and moderate doses.
Additional summary measures of gametocyte
persistence
Gametocyte clearance time or duration of gametocyte
carriage (the length of time each person has gametocytes)
Seven trial authors presented gametocyte clearance time (the num-
ber of hours or days until gametocytes disappear, sometimes de-
scribed as “duration of gametocyte carriage”). Pukrittayakamee
2004 makes a distinction between these two parameters, with ga-
metocyte carriage adjusting for intermittent periods of time with-
out gametocytes.
Using microscopy, at low dose, Tine 2017 reported that duration
of gametocyte carriage was reduced from average of 1.08 days in
the ACT only group to 0.29 days in the ACT plus PQ group. In
Lin 2017 (high dose), median time to clearance was reduced from
12 days in non PQ group to 1 day in the PQ group.
At low and moderate doses, Gonçalves 2016b showed that mean
gametocyte clearance time (by PCR) was reduced on average by
12 days (95% CI −12.83 to −11.17) in the low dose group and
by 11.5 days (−12.33 to -10.67) in the moderate dose group
(Analysis 1.7).
In Eziefula 2013, also by PCR, the gametocyte clearance time was
not significantly longer in the 0.4 mg/kg group (6.3 days, 95%
CI 5.1 to 7.5) than the 0.75 mg/kg group (6.6 days, 95% CI 5.3
to 7.8). However the 0.75 mg/kg group had significantly shorter
gametocyte clearance time than the placebo group (12.4days, 95%
CI 9.9 to 15.0).
Two other trials reported results for the 0.75 mg/kg dose. Game-
tocyte clearance time in days was presented in Shekalaghe 2007
and was significantly shorter (by PCR) in the PQ group (6.3 days,
95% CI 4.7 to 8.5) than in the non-PQ group (28.6 days, 95%
CI 17.0 to 48.0, P < 0.001). Smithuis 2010, using microscopy,
also reported significantly shorter gametocyte clearance time in
the PQ groups, reported as person-gametocytaemia-weeks stan-
dardized per 1000 person-weeks of follow-up. This was 5.5 weeks
in the ACT+PQ groups versus 65.5 weeks in the non-PQ groups
(RR 11.9, 95% CI 7.4 to 20.5, P < 0.001) and the difference was
very large for each individual malaria treatment regimen (five dif-
ferent ACTs or formulations were tested). Although the duration
of gametocyte carriage (without PQ) was significantly longer for
AS+AQ, AL andDHAP than for AS+MQ, there was no difference
in length of gametocyte carriage between the ACT groups when
PQ was added (Smithuis 2010).
Pukrittayakamee 2004 reported reduction in median gametocyte
clearance time from 138 (range 12 to 264) hours with artesunate
alone to 73 (range 6 to 145) hours with artesunate and 7 days of
PQ (0.5 mg/kg).
Gametocyte circulation time
Another outcome related to gametocytes estimated by PCR in
Eziefula 2013 and Shekalaghe 2007 was the mean life (circulation
time) of gametocytes (this is reported per gametocyte rather than
per person as for gametocyte clearance time above). In Eziefula
2013 the circulation time per gametocyte was significantly longer
in the placebo group (1.97 days, 95% CI 1.64 to 2.31). than in
the other two groups (0.95 and 0.98 days in the 0.4 and 0.75 mg/
kg groups respectively). In Shekalaghe 2007, themean gametocyte
circulation time was reduced from 4.6 days (95% CI 2.9 to 7.3)
after AS+SP alone to 0.5 days (95% CI 0.2 to 1.2) after AS+SP
plus 0.75 mg/kg PQ (P < 0.001).
Area under curve of gametocyte density over time
Area under curve combines measures of density over time. Trials
varied in the follow-up time completed. Using microscopy, Tine
2017 observed reduction of AUC (follow-up to day 29) from
106.7 in the ACT+PQ group to 29.5 in the ACT only group.
Gametocyte density by PCR over time was reported in four trials.
For low andmoderate dose, Gonçalves 2016b reported a reduction
of the mean AUC (up to day 15) of −9.20 (−10.79 to −7.61)
for low dose and −9.10 (−10.50 to −7.70) for moderate dose
(Analysis 1.8). Eziefula 2013 also used a duration of 15 days to
estimate AUC using PCR and found that the log(10)AUC in each
intervention group was not significantly different from placebo. It
was 3.8 (95% CI 1.7 to 8.2) gametocytes per µL per day in the
placebo group, 2.1 (1.0 to 4.5) in the 0.4 mg/kg group, and 2.0
(0.9 to 4.3) in the 0.75 mg/kg group.
Using PCR-detected gametocyte density estimates, Shekalaghe
2007 provided geometric mean and interquartile range (IQR) val-
ues on days 1, 4, 8, 15, 29, and 43. Mean density was consistently
lower in the 0.75 mg/kg PQ than the non-PQ group, for days
when gametocytes were detected (with PQ: 5.8, IQR 0.8 to 55.1;
without PQ: 15.8, IQR 4.1 to 85.8). Shekalaghe 2007 also pre-
sented a statistical comparison of AUC of gametocyte density (by
PCR) over a 43-day period, with a 95% CI derived from gener-
alized estimation equations. There was a significant reduction in
AUC in the 0.75 mg/kg PQ groups over 43 days after treatment,
reported as mean of 1.5 (IQR 0.3 to 8.8) in the PQ group versus
11.1 (IQR 2.2 to 53.8) in the non-PQ group (P < 0.001).
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Haemolytic adverse effects
Severe haemolysis
At the low dose, four trials evaluated severe haemolysis defined
as drop of ≥ 25% (Dicko 2016; Mwaiswelo 2016), or ≥ 2 g
in haemoglobin (Gonçalves 2016b; Tine 2017) over the course
of follow-up; only three of these trials had such events (Analysis
1.9). The results given for Gonçalves 2016b included combined
data from Gonçalves 2016a as they were not reported separately.
Dicko 2016 and Gonçalves 2016b excluded G6PD deficient in-
dividuals identified by fluorescent spot test (FST) or the rapid
test; Mwaiswelo 2016 and Tine 2017 screened participants but
did not exclude those with G6PD deficiency. Severe haemolysis
as defined above was no different in frequency between the PQ
group (12.3% of 381 participants) than the control group (13.2%
of 371 participants).
Mwaiswelo 2016 (low dose) also reported an outcome of “acute
haemolytic anaemia”, experienced by 2.8% of participants in both
PQ and control groups (109 participants and 108 participants
respectively).
Severe haemolysis was reported for the moderate dose for two
trials (Dicko 2016; Gonçalves 2016b), of which only the latter
had any events (Analysis 1.9) . No difference was observed in
the proportion of participants with this outcome between the PQ
group (3.7% of 136 participants) and the control group (2.4% of
124 participants).
At high dose, Smithuis 2010 stated that there were no cases of se-
vere anaemia (< 5 g/dL) or blackwater fever in any ACT or control
group. Shekalaghe 2007 stated that eight of 52 children in the PQ
group had a 20% reduction in haemoglobin by day 8, compared
to 0 of 53 children in the control group. However, Shekalaghe
2007 also stated that no child developed clinical symptoms related
to anaemia or a haemoglobin below 5 g/dL.
Other measures of anaemia or haemoglobin
Measures of haemoglobin or PCV at day 8
No trials at low or moderate dose reported these outcomes. At
high dose Shekalaghe 2007 and Sutanto 2013 found no difference
between groups in mean haemoglobin at day 8. Also using high
dose, El-Sayed 2007 showed that there was no difference in PCV
between groups at day 8: 34.2% (15% to 44%) versus 36.2%
(26% to 42%).
Maximum change in haemoglobin concentration
The maximum change in haemoglobin concentration (over all
days of follow-up) was measured in three trials, two of which
reported results separately by G6PD status (Eziefula 2013;
Mwaiswelo 2016), while the other did not (Okebe 2016). In gen-
eral, change in haemoglobinwas less in the control than PQ groups
(Analysis 1.10), but results were heterogenous especially at the low
dose where themean difference was 0.13 (−0.07 to 0.33) g of hae-
moglobin (random-effects model). The change in haemoglobin
by day 8 (rather than any day) was reported in Tine 2017 and is
included in Analysis 1.10. In the moderate and high dose groups,
the mean difference was 0.18 (−0.08 to 0.44) and 0.05 (−0.04
to 0.14), respectively.
Percentage change in haemoglobin by day 8
Using percentage change by day 8 (rather than absolute haemoglo-
bin concentration at that time), the low, moderate, and high dose
PQ groups were not different from the control groups (Analysis
1.11), but heterogeneity was high, especially at low dose. Some
trials reported this outcome separately by G6PD status, and if so,
the results were presented separately (see footnotes).
Maximum percent change in haemoglobin
The maximum percent decrease in haemoglobin (by any day of
follow-up) was also reported in three trials, one in each dose cat-
egory (Analysis 1.12). In low and moderate dose, the maximum
percent decrease was larger in the PQ group than control, but the
opposite was seen for high dose.
Haemoglobinuria or dark urine
The presence of haemoglobinuria/dark urine was reported by
Dicko 2016 (low and moderate dose, but with no events in the
latter), Mwaiswelo 2016 (low dose), and Tine 2017 (low dose)
and is shown in Analysis 1.13. These adverse effects were more
than three times more likely in the PQ group (RR 3.40, 95% CI
2.15 to 5.38; 3 trials (4 arms), 527 participants) than the control
group.
Other adverse effects
These outcomes were not classified by dose. Frequencies of
headache, fatigue, nausea, vomiting, abdominal pain, diarrhoea,
pruritis, paraesthesia, fever, cough, runny nose, muscle ache/pain,
dizziness, upper respiratory infections, back pain, burning or
pain with urination, bronchitis, rhinitis/rhino bronchitis, short-
ness of breath, whitlow, leg osteoarthritis, malaria, otitis, epis-
taxis, dental pain, high transaminase, palpebral inflammation, foot
trauma or inflammation, skin infection or rash, pallor, pneumo-
nia, meningitis, blurred vision, cold sore, weakness/asthenia, pal-
pitations, cyanosis, insomnia, or unspecified other event were not
increased in the PQ groups (Analysis 1.14; Analysis 1.15; Analy-
sis 1.16; Analysis 1.17; Analysis 1.18) as reported in Wang 2006;
Smithuis 2010; Dicko 2016; Gonçalves 2016a; Gonçalves 2016b;
Mwaiswelo 2016; Okebe 2016; and Tine 2017, with one to 11
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trial arms per event type reported. Small differences in frequencies
between PQ and control groups are noted for anorexia (increased
in PQ group) and wound/trauma (decreased in PQ group).
2. Comparison of low and moderate doses
(artemisinin partner only)
Given the importance of confirming effectiveness of the low dose,
and that fact that four trials included groups randomized to low
and moderate doses, we compared these two doses directly.
Follow-up at day 3 or 4
Infectiousness of people to mosquitoes
Only one of three trials had any infectious events: one infectious
person in each of the PQ and non-PQ groups, total 116 partici-
pants (Analysis 2.1). The RR was 0.93 (95% CI 0.06 to 13.54; 3
trials, 116 participants).
Gametocyte prevalence by PCR
Comparing the low and moderate groups, there was no difference
in the proportion of participants with gametocytes by PCR (RR
0.93, 95% CI 0.80 to 1.09; 3 trials, 424 participants (Analysis
2.2).
Gametocyte prevalence by microscopy
In two trials (both in same location) that reported this outcome,
there was also no difference in the proportion of participants with
gametocytes detected by microscopy (RR 1.23, 95% CI 0.68 to
2.20; 2 trials, 231 participants; Analysis 2.3).
Follow-up at day 8
Infectiousness of people to mosquitoes
In four trials, two of which had infectious events, there was no
evidence of any difference in effect on proportion of participants
infectious between low and moderate doses (RR 0.95, 95% CI
0.14 to 6.48; 4 trials, 237 participants; Analysis 2.4).
Gametocyte prevalence by PCR
There were four trials reporting gametocyte prevalence by PCR at
day 8. The evidence suggested the effect tended to be greater at
moderate than low dose (RR 1.33, 95% CI 0.97 to 1.82; 4 trials,
559 participants; Analysis 2.5).
Gametocyte prevalence by microscopy
Two trials, both in the same site, showed the same trend as for
PCR but no greater effect of moderate dose at day 8 (RR 1.80,
95% CI 0.51 to 6.38; 2 trials, 235 participants; Analysis 2.6).
3. PQ as part of non-artemisinin-based treatment
regimens
Eleven trials contributed comparisons to this analysis, of which
one trial tested both low dose and moderate dose PQ regimens
over seven days (Pukrittayakamee 2004), and one trial (two com-
parisons) tested moderate dose PQ (Kolaczinski 2012). The re-
mainder were high dose.
We could not use data from one trial with non-artemisinin partner
CQ because it did not distinguish between patients with P. falci-
parum and P. vivax and their respective treatments (Khoo 1981).
There was a much higher risk of adverse haemolytic events in
those who received PQ in the Khoo 1981 trial (OR 22.27 for
both haemolysis and need for blood transfusion), but we could
not include the results because the groups combined participants
receiving a short course (three days) of PQ with those receiving a
14-day regimen. The most unusual aspect of the trial, however, is
that it included only individuals with G6PD deficiency.
Follow-up at day 5
Infectiousness of people to mosquitoes
No trials tested the low or moderate dose for effect on infectious-
ness with non-artemisinin partners.
Using high dose, two small trials in China (Chen 1993a; Chen
1994), with only six and nine participants per group, respectively,
directly tested the impact of PQ added to MQ on infectiousness
to mosquitoes. The proportion of people infectious was reduced
to 0% in the PQ group when measured on day 5, compared to
66.7% in the control group (RR 0.09 (95% CI 0.01 to 0.62; 2
trials, 30 participants; Analysis 3.1).
Infections acquired by mosquitoes
Chen 1994 reported the number ofmosquitoes infected after feed-
ing on trial participants. None of the mosquitoes feeding on peo-
ple receiving PQ were infected, with over 64% infected at day 5
after feeding on the group not receiving PQ,
Gametocyte prevalence by PCR
Notrialswith non-artemisinin partners assessed gametocyte preva-
lence by PCR.
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Gametocyte prevalence by microscopy
Two trials each at the moderate and high doses showed no differ-
ence in the gametocyte prevalence at day 4-5 (Analysis 3.2); RR
0.83 (95%CI 0.62 to 0.13; one trial (two arms), 221 participants)
for moderate dose and RR 0.85 (95% CI 0.48 to 1.50; 2 trials, 52
participants) for the high dose.
Follow-up at day 8
Infectiousness of people to mosquitoes
The two Chinese trials with MQ partner using high dose showed
a similar effect at day 8 as at day 5 above: the proportion of infec-
tious people was 93% in control group and 0% in the PQ group.
(Analysis 3.3). RR 0.07 (95% CI 0.01 to 0.45; 2 trials, 30 partic-
ipants).
Infections acquired by mosquitoes
Chen 1994 reported the number ofmosquitoes infected after feed-
ing on trial participants. None of the mosquitoes feeding on peo-
ple receiving PQ were infected, with 54% infected at day 8 after
feeding on the group not receiving PQ.
Gametocyte prevalence by PCR
Notrialswith non-artemisinin partners assessed gametocyte preva-
lence by PCR.
Gametocyte prevalence by microscopy
At day 8 one trial (two arms) reported gametocyte prevalence at
moderate dose (reduction of 40%); RR 0.60 (95% CI 0.49 to
0.75; 216 participants) and four trials (five arms) at the high dose
(reduction of 61%) (RR 0.39, 95% CI 0.25 to 0.62; 4 trials, 186
participants; Analysis 3.4).
Additional summary measures of gametocyte
persistence
Gametocyte clearance time or duration of gametocyte
carriage (the average number of days each person has
gametocytes)
The median gametocyte clearance time was reduced in
Pukrittayakamee 2004 (two comparisons; partner QN) from 48
(range: six to 324) hours with low dose PQ, and from 216 (range:
six to 624) hours with quinine only to 87 (range: five to 207 hours)
hours with moderate dose PQ. There was no difference between
the median clearance time in the two PQ arms (P = 0.45).
Using high dose, gametocyte clearance time (in days) was signifi-
cantly reduced in the PQ group in Singhasivanon 1994 (which had
MQ+SP partner) with a mean difference of −14.90 days (95%
CI −18.18 to −11.62; Analysis 3.5).
Adverse events
The trials with non-artemisinin partner regimens did not report
adverse effects well or consistently. None of these trials reported
on haemolysis, other haematological measures, or severe adverse
events.
Singhasivanon 1994 using high dose found no difference in fre-
quency of reported adverse effects (nausea, vomiting or dizziness)
over 28 days follow-up (Analysis 3.6).
4. Comparison of different 8AQ
Follow-up at day 8
Two small trials compared the effect of bulaquine and PQ (0.75
mg/kg) on gametocyte prevalence at day 8 (Gogtay 2004; Gogtay
2006). Both trials suggested a greater reduction of gametocytes by
bulaquine (RR 0.41, 95% CI 0.26 to 0.66; 2 trials, 112 partici-
pants; Analysis 4.1). Neither trial concealed allocation.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Moderate-dose primaquine (PQ) given with artemisinin combination treatment
Participants or population: adults and children with malaria being treated with artemisinin combinat ion treatment
Settings: Mali, Burkina Faso, The Gambia, Uganda
Intervention: single dose PQ 0.4 to 0.5 mg/ kg
Comparison: no PQ
Outcomes Number of participants
(trials)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
Risk with no PQ, with
artemisinin partner,
Risk with single dose
PQ at 0.4 to 0.5 mg/kg
Part icipants infect ious
at day 3-4
109
(3 RCTs)
RR 0.13
(0.02 to 0.94)
14 per 100 2 per 100
(0 to 13)
⊕⊕©©
LOW1
Due to imprecision
Medium dose PQ may
reduce infect iousness
Part icipants infect ious
at day 8
246
(4 RCTs)
RR 0.33
(0.07 to 1.57)
4 per 100 1 per 100
(0 to 6)
⊕⊕©©
LOW1
Due to imprecision
Medium dose PQ may
reduce infect iousness
Part icipants with game-
tocytes at day 3-4, by
PCR
418
(3 RCTs)
RR 1.09
(0.93 to 1.28)
52 per 100 57 per 100
(48 to 67)
⊕⊕⊕©
MODERATE2
Due to imprecision
Medium dose PQ prob-
ably has lit t le or no
ef fect on gametocytes
detected by PCR on day
3 to 4
Part icipants with game-
tocytes at day 8, by PCR
758
(5 RCTs)
RR 0.37
(0.29 to 0.48)
43 per 100 16 per 100
(13 to 21)
⊕⊕⊕⊕
HIGH
Medium dose PQ re-
duces gametocytes de-
tected by PCR on day 8
Part icipants with se-
vere haemolysis
260
(2 RCTs)
RR 1.54
(0.38 to 6.30)
2 per 100 4 per 100
(1 to 15)
⊕⊕©©
LOW3
Due to imprecision
Medium dose PQ
may increase severe
haemolysis
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
Abbreviations: CI: conf idence interval; PCR: polymerase chain react ion; RCT: randomised controlled trial; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 2 for imprecision: the CIs are wide; in addit ion, there is a large ef fect combined with a low number of events,
which creates further uncertainty around the point est imate.
2Downgraded by 1 for imprecision: the CIs are wide.
3Downgraded by 2 for imprecision: the CIs are very wide.
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High-dose primaquine (PQ) given with artemisinin combination treatment
Participants or population: adults and children with malaria being treated with artemisinin combinat ion treatment
Settings: Cambodia, Mali, Burkina Faso, The Gambia, Tanzania, Sudan, Uganda
Intervention: single dose PQ 0.75 mg/ kg
Comparison: no PQ
Outcomes Number of participants
(trials)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
Risk with no PQ, with
artemisinin partner
Risk with single dose
PQ at 0.75mg/kg
Part icipants infect ious
at day 3-4
101
(1 RCT)
RR 0.20
(0.02 to 1.68)
10 per 100 2 per 100
(0 to 16)
⊕⊕©©
LOW1,2
Due to imprecision
We do not know if high
dose PQ may reduce in-
fect iousness
Part icipants infect ious
at day 8
181
(2 RCTs)
RR 0.18
(0.02 to 1.41)
5 per 100 1 per 100
(0 to 8)
⊕⊕©©
LOW1
Due to imprecision
High dose PQ may re-
duce infect iousness
Part icipants with game-
tocytes at day 3-4, by
PCR
290
(2 RCTs)
RR 0.92
(0.75 to 1.13)
38 per 100 35 per 100
(29 to 43)
⊕⊕©©
LOW3,4
Due to indirectness and
imprecision
High dose PQ may have
lit t le or no ef fect on ga-
metocytes detected by
PCR
Part icipants with game-
tocytes at day 8, by PCR
793
(5 RCTs)
RR 0.31
(0.23 to 0.43)
36 per 100 11 per 100
(8 to 16)
⊕⊕⊕⊕
HIGH
High dose PQ reduces
gametocytes detected
by PCR
Part icipants with se-
vere haemolysis
106
(1 RCT)
No est imate Not est imable Not est imable No data We don’t know if high
dose PQ impacts on
haemolysis
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; PCR: polymerase chain react ion; RCT : randomised controlled trial; RR: risk rat io; OR: odds rat io.
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 2 for imprecision: the CIs are wide; in addit ion, there is a large ef fect combined with a low number of events,
which creates further uncertainty around the point est imate. In addit ion, in this one trial baseline.
2Baseline values for this outcome were unbalanced, but the downgrading by 2 for imprecision takes this in to account, as it
could be a chance f inding.
3Downgraded by 1 for indirectness: all the data for the results come f rom one trial.
4Downgraded by 1 for imprecision: the CIs are wide.
2
6
P
rim
a
q
u
in
e
o
r
o
th
e
r
8
-a
m
in
o
q
u
in
o
lin
e
s
fo
r
re
d
u
c
in
g
P
la
sm
od
iu
m
fa
lcip
a
ru
m
tra
n
sm
issio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Moderate-dose primaquine (PQ) given with non-artemisinin treatment
Participants or population: adults and children with malaria being treated with non-artemisinin treatment
Settings: Pakistan
Intervention: single dose PQ 0.4 to 0.5 mg/ kg
Comparison: no PQ
Outcomes Number of participants
(trials)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
Risk with no PQ, with
non-artemisinin part-
ner
Risk with single dose
PQ at 0.4 to 0.5 mg/kg
Part icipants with game-
tocytes at day 4-5, by
microscopy
221
(2 RCTs)
RR 0.83
(0.62 to 1.13)
48 per 100 40 per 100
(30 to 54)
⊕⊕⊕©
MODERATE 1
Due to indirectness
Medium dose PQ prob-
ably reduces gameto-
cytes detected by mi-
croscopy
Part icipants with game-
tocytes at day 8, by mi-
croscopy
216
(2 RCTs)
RR 0.60
(0.49 to 0.75)
81 per 100 49 per 100
(40 to 61)
⊕⊕⊕©
MODERATE 1
Due to indirectness
Medium dose PQ prob-
ably reduces gameto-
cytes detected by mi-
croscopy
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for indirectness: all the results are f rom one sett ing.
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Medium-dose primaquine (PQ) given with non-artemisinin treatment
Participants or population: adults and children with malaria being treated with non-artemisinin treatment
Settings: China, Colombia, India, Indonesia
Intervention: single dose PQ 0.75 mg/ kg
Comparison: no PQ
Outcomes Number of participants
(trials)
Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Certainty of the evi-
dence
(GRADE)
Comments
Risk with no PQ, with
non-artemisinin part-
ner
Risk with single dose
PQ at 0.75 mg/kg
Part icipants infect ious
at day 5
30
(2 RCTs)
RR 0.09
(0.01 to 0.62)
67 per 100 6 per 100
(1 to 41)
⊕©©©
VERY LOW1,2
Due to risk of bias and
imprecision
We are uncertain
whether high dose PQ
reduces infect iousness
Part icipants infect ious
at day 8
30
(2 RCTs)
RR 0.07
(0.01 to 0.45)
93 per 100 7 per 100
(1 to 42)
⊕©©©
VERY LOW1,2
Due to risk of bias and
imprecision
We are uncertain
whether high dose PQ
reduces infect iousness
Part icipants with game-
tocytes at day 5, by mi-
croscopy
52
(2 RCTs)
RR 0.85
(0.48 to 1.50)
50 per 100 43 per 100
(24 to 75)
⊕⊕©©
LOW3,4
Due to risk of bias and
imprecision
High dose PQ may re-
duce gametocytes de-
tected by microscopy
Part icipants with game-
tocytes at day 8, by mi-
croscopy
186
(4 RCTs)
RR 0.39
(0.25 to 0.62)
48 per 100 19 per 100
(12 to 29)
⊕⊕⊕©
MODERATE5
Due to risk of bias
High dose PQ prob-
ably reduces gameto-
cytes detected by mi-
croscopy
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io; OR: odds rat io.
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded by 1 for risk of bias: unclear risk of bias in several domains f rom both studies.
2Downgraded by 2 for imprecision: the CIs are wide; in addit ion, there is a large ef fect combined with a low number of events,
which creates further uncertainty around the point est imate.
3Downgraded by 1 for risk of bias: Arango 2012 had serious risk for select ion bias and Chen 1993a had unclear risk of bias in
several domains.
4Downgraded by 1 for imprecision: the CIs are wide.
5Downgraded by 1 for risk of bias: Arango 2012 had serious risk for select ion bias and Chen 1993a had unclear risk of bias in
several domains. Kamtekar 2004 had serious risk of bias for several domains.
2
9
P
rim
a
q
u
in
e
o
r
o
th
e
r
8
-a
m
in
o
q
u
in
o
lin
e
s
fo
r
re
d
u
c
in
g
P
la
sm
od
iu
m
fa
lcip
a
ru
m
tra
n
sm
issio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
A
u
th
o
rs.
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
D I S C U S S I O N
Summary of main results
We included 24 RCTs and one quasi-RCT. Sixteen trials included
study arms with artemisinin-based treatments, 11 trials included
study arms with non-artemisinin-based treatments, and two trials
included both types of partner arms. Fifteen trials tested for G6PD
status: ten then excluded participants with G6PD deficiency, one
included only those with G6PD deficiency, and four included all
irrespective of status. The remaining 10 trials either did not report
on whether they tested (eight trials), or reported that they did not
test (two trials). No trials evaluated community effects on malaria
transmission.
With artemisinin combination treatment
See Summary of findings for the main comparison, Summary of
findings 2 and Summary of findings 3 for low, moderate, and high
dose with artemisinin partner drugs, respectively.
Low-dose PQ
Infectiousness to mosquitoes was reduced (Iow certainty evidence).
For gametocytes detected by PCR, there was little or no effect of
PQ at day 3 or 4 (moderate certainty evidence) with clear reduction
at day 8 (high certainty evidence). Low-dose PQ probably has little
or no effect on severe haemolysis (moderate certainty evidence).
Moderate-dose PQ
Infectiousness to mosquitoes was reduced (low certainty evidence).
The pattern and level of certainty of evidence with gametocytes
detected by PCR was the same as low dose (moderate and high at
days 3 or 4 and 8 respectively, and severe haemolysis was infrequent
in both groups (low certainty evidence).
High dose PQ
Infectiousness to mosquitoes was reduced (low certainty evidence).
The effects on gametocyte prevalence showed a similar pattern to
moderate and low dose PQ (low and high certainty at days 3 or 4
and 8 respectively). Evidence of haemolysis was not systematically
sought in this dose group.
With non-artemisinin treatment
See Summary of findings 4 and Summary of findings 5 for moder-
ate and high dose with non-artemisinin partner drugs respectively.
Trials have been conducted only in the moderate- and high-dose
PQ categories. Two small trials from the same laboratory in China
evaluated infectiousness to mosquitoes with high dose PQ, report-
ing that infectiousness was reduced markedly on day 5 and on day
8 (very low certainty evidence).
Reduction in gametocytes, detected in this case by microscopy,
showed similar patterns to the artemisinin-based treatments. For
moderate dose, there was little or no effect at day 4 or 5 (moderate
certainty evidence), and larger effect by day 8 (moderate certainty
evidence). At high dose, findings were similar but certainly of evi-
dence was low at day 4 to 5. No trials with non-artemisinin part-
ners systematically sought evidence of severe haemolysis.
Two small trials comparing bulaquine with PQ suggest bulaquine
may have larger effects on gametocytes (by microscopy) on day 8.
Overall completeness and applicability of
evidence
What is known
This review update adds recently available evidence on infectious-
ness of people with falciparum malaria treated with low and mod-
erate PQ doses in addition to primary treatment. It also includes
additional evidence on the effect of PQ at different doses on ga-
metocyte prevalence at two time points after treatment. Previously
only indirect evidence was available (for example, Bunnag 1980,
with no difference in gametocyte outcomes between 15 mg PQ
for five days in children, and single doses of 30 mg or 45 mg PQ
in adults), in narrative summaries and analyses that have proposed
widespread programmatic implementation of PQ (White 2012;
White 2013).
Adding PQ at around 0.25 mg/kg to treatment using artemisinin-
based combination therapies reduces infectiousness to mosquitoes
at day 3 to 5 and at day 8 after treatment. These data come
from four trials conducted in Burkina Faso (with AL partner)
(Gonçalves 2016a; Gonçalves 2016b) Gambia (DHAP) (Okebe
2016), andMali (DHAP) (Dicko 2016).One other trial usinghigh
dose also reported on infectiousness in Cambodia with DHAP
partner (Lin 2017). Two of these trials included only gameto-
cyte carriers at screening (Dicko 2016; Gonçalves 2016b). Due to
relatively low proportion of infectious individuals among treated
malaria patients (even those with gametocytes), the absolute re-
duction in proportion of people infectious is not large. The abso-
lute reduction in proportion of mosquitoes infected was also low.
The effect on infectiousness was more marked at day 3 or 4 than
day 8, which reflects the declining infectiousness in the non-PQ
control groups by this time. Unlike the pattern seen in reducing
infectiousness, there was little reduction by PQ with artemisinin
partners in gametocyte prevalence at day 3 or 4 with the low or
moderate dose. By day 8, large effects of PQ on gametocyte preva-
lence were seen. Reductions in gametocyte clearance time were
also dramatic. The results come from trials in different epidemio-
logical settings and with a variety of artemisinin-based treatments
(Burkina Faso: AL (Gonçalves 2016a; Gonçalves 2016b); Cam-
bodia: DHAP (Lin 2017); Colombia: AS+MQ (Vásquez 2009;
Arango 2012); Gambia: DHAP (Okebe 2016); Senegal: DHAP,
30Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
AL, and ASAQ (Tine 2017); Indonesia: DHAP (Sutanto 2013);
Mali: DHAP (Dicko 2016); Myanmar: AS+MQ, DHAP, AL and
ASAQ (Smithuis 2010); Sudan: AS+SP (El-Sayed 2007); Tanza-
nia: AS+SP (Shekalaghe 2007); Thailand: AS (Pukrittayakamee
2004); and Uganda: AL (Eziefula 2013)).
In terms of safety, adverse effects of PQ in people with G6PD defi-
ciency are less common with lower doses of PQ (Olalekan 2017),
although direct comparisons are few and sample sizes small. Most
trials included in this review excluded individuals with G6PD de-
ficiency, but some included them, did not test for it or did not
state whether they tested; thus some trials included some G6PD
deficient participants. However, few severe haematological effects
were reported (Shekalaghe 2007; Dicko 2016; Gonçalves 2016b;
Mwaiswelo 2016; Tine 2017).
What is unknown
While reducing infectiousness to mosquitoes and the duration and
density of gametocytaemia can be assumed to reduce transmis-
sion to mosquitoes at the level of the individual, it remains un-
clear whether it will impact materially on community level trans-
mission, as reliable trials have never evaluated this. We excluded
from this review several older trials, which are often cited as proof
of an effect on community transmission, because either: i) they
lacked an adequate control group with partner drug but without
PQ (Clyde 1962); ii) they did not apply the interventions equally
in intervention and control groups or had no ‘before’ data (Doi
1989; Kaneko 1989); iii) they administered PQ alongside vector
control co-interventions, whichmay equally be responsible for any
effect seen (Hii 1987; Kaneko 2000); or iv) they administered PQ
or 8AQ alone and not alongside treatment regimens (which is the
policy currently recommended) (Barber 1932).
Many gametocyte carriers are asymptomatic and unlikely to seek
treatment, at least in areas of moderate to high transmission where
most adults have a level of acquired immunity that reduces the
probability that parasitaemia will cause clinical symptoms. There-
fore, since a minority of infected persons seek treatment, it is un-
clear whether a policy of adding PQ tomalaria treatment regimens
will reduce malaria transmission at a community level. Johnston
2014 modelled the effect of treatment, and concluded that the
most important factor predicting success is the percentage of in-
fected individuals treated with an ACT, and that adding PQ is
of negligible benefit. Johnston and colleagues estimated that “it
would require switching 180 people from ACTs to ACTs plus PQ
to achieve the same transmission reduction as switching a single
individual from untreated to treated with ACTs”.
The relative contribution of symptomatic and asymptomatic ga-
metocyte carriers to the infectious reservoir in the population, as
well of the relative infectiousness of gametocytes detected by mi-
croscopy and PCR, are areas of active research (Stone 2015). The
proportion of asymptomatic carriers varies according to the level of
transmission, with low density infections comprising a large pro-
portion of infections in low transmission areas (Gerardin 2015a).
If most infectious individuals are not among the care-seeking pop-
ulation, they can only be reached by proactive strategies such as
‘mass screen and treat’ or mass treatment programmes.
Mass treatment programmes (where everyone in the community
is treated at specified intervals until transmission is stopped) are
a potential strategy to reach asymptomatic gametocyte carriers
(von Seidlein 2003; GMAP 2008; Mendis 2009; Sturrock 2013).
However, in theory, mass treatment consisting only of primary
treatment (an ACT alone) could interrupt transmission, and the
additional effects of adding PQ (interrupting transmission more
quickly, or at a lower coverage levels) have not been demonstrated
(Poirot 2013). Gerardin 2015b modelled the impact of adding
PQ to either AL or DHAP in mass treatment programs. and con-
cluded that it would be most effective in combination with a long
acting partner such as DHAP and where most of the population
is protected against reinfection; otherwise, if transmission is high,
the effect of adding PQwould be ‘negligible’. A similar conclusion
was reached by the WHO Malaria Policy Advisory Committee
(MPAC) through consensus modelling (WHO 2015c).
Infectiousness of a population to mosquitoes comprises two ele-
ments: the proportion of people who are infectious, and the pro-
portion of mosquitoes infected after feeding on an infectious per-
son. The two factors can be multiplied together to arrive at a com-
bined ‘mosquito infection probability’ (Graves 1990; Stone 2015),
representing the likelihood of a mosquito acquiring infection after
feeding on a member of the population. Considering only reduc-
tion in the proportion of infectious individuals may underestimate
the impact of PQ, although evidence from the trials included here
does not suggest large reduction in the proportion of mosquitoes
infected by persons remaining infectious after treatment (Table
2; Table 3; Table 4). Larger sample sizes of infectious people are
required.
The relative effect of PQon infectiousness when added to different
artemisinin drugs is not well understood and needs to be empiri-
cally studied further, since it known that there is variation between
them in gametocytocidal activity (WWARN 2016). Two studies
included here compared multiple ACTs (AL, AS+MQ, ASAQ,
and DHAP) (Smithuis 2010; Tine 2017), but no infectiousness
data were included.
The ability to metabolize PQ to active ingredients (dependent on
human cytochrome P-450 enzyme (CYP2D6)) may also affect
its impact, since alleles conferring low and intermediate metabo-
lizer phenotypes are unable to reap the benefits of PQ (Bennett
2013;Meltzer 2014). In this review, Eziefula 2013 reported on the
CYP2D6 phenotypes of participants. Since this may be a factor
in heterogeneity of effects observed, further study of geographical
distribution of these variant phenotypes affecting ability to utilize
PQ is needed to determine their impact on the effectiveness of PQ
on gametocytes and for reducing transmission.
The trials included in this review do not mention PQ resistance as
a potential threat. PQ clearly should be used where it is of clinical
importance, especially for P. vivax and P. ovale. Its effectiveness
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against those parasites could be compromised by resistance if used
at low doses in populations where P. falciparum, P. vivax, and P.
ovale coexist. As for all antimalarial drugs, there is a global respon-
sibility to maintain the effectiveness of PQ for as long as possible
without withholding it when needed. In this case, that translates
into using it to reduce transmission only if there is reasonable evi-
dence that it actually has that effect. Otherwise, it will be used to
little or no effect but its value for radical cure may be diminished
by the development of resistant Plasmodium parasites.
Quality of the evidence
In our hierarchy of study types, the strongest, most direct evidence
for an effect of PQ on falciparum malaria transmission would
come from trials that randomize entire communities to treatment
with and without PQ and then monitor malaria prevalence over a
period of years.No such trials-at any dose orwith any partner drug-
met the inclusion criteria. The evidence is, therefore, all indirect,
requiring some untested assumptions in evaluating an effect of
single dose PQ on malaria transmission.
The evidence is also predominantly for higher PQ doses than
the 0.25 mg/kg currently recommended by the WHO. Out of
40 total trial arms that met the inclusion criteria and reported
gametocyte outcomes, only five used a low dose (0.20 to 0.25 mg/
kg). The remaining arms provide evidence, but the exact dose-
response relationship that would apply to single dose PQ is not
known, so again, some assumptions are needed to evaluate the
relevance of this information.
Second in our evidence hierarchy were trials of the infectiousness
of treated individuals to mosquitoes, of which there were four at
the low dose of PQ. However, all four trials did not report all
key data. Summing up, the infectiousness results for the low dose
are based mainly on the results from only one trial (Dicko 2016),
which observed one versus seven infectious events at day 3, and 0
versus 3 events at day 8 in the PQ and non-PQ groups respectively.
Thus, despite the inclusion of several new trials with infectious-
ness data in this update, the evidence for reduction is inconsis-
tent and based on a very small number of trials and events. The
three infectiousness trials at higher PQ doses reported significant
declines, but once again, the relevance to lower doses is uncertain.
Most of the included trials were on the next rung of the hierar-
chy: the effect of PQ on circulating gametocytes in people treated
with andwithout PQ (potential infectiousness). The included trial
arms span decades of research, including many conducted before
the artemisinin era. Out of 40 arms, 16 were with non-artemisinin
partners (which also used higher PQ doses). Artemisinin drugs
themselves have some impact on gametocytes, so how well the
earlier evidence reflects the impact of an artemisinin derivative
plus PQ is also unknown. Nonetheless, results of these trials were
generally consistent. Differences in gametocyte detection method
(microscopy or PCR) made synthesis somewhat difficult, but po-
tential infectiousness is the most convincing and robust evidence
for a possible effect on transmission, under the right conditions.
The included trials do not provide sufficient evidence to evaluate
the safety of this intervention. Many trials did not test for G6PD
deficiency, and of those that did, most excluded deficient individ-
uals. The trials were, by and large, not designed for safety evalua-
tions.
Overall, the evidence of efficacy is limited in both quality and
quantity, and it is all indirect, to varying degrees.
Potential biases in the review process
We have identified three potential biases or deficiencies in the
search and review processes.
First, three trials could not be located. Two were earlier trials (pub-
lication dates 1993 and 2006) in Chinese; one was a conference
abstract from 2009. Second, we restricted follow-up only to day
8 because most persons were non-infectious by then. Third, we
stratified by artemisinin/non-artemisinin drugs, since the former
are the recommended treatments in the majority of malaria-en-
demic areas. We believe these decisions should have no material
impact on the results, but could be challenged.
Agreements and disagreements with other
studies or reviews
A historical review of patients treated at clinics in India with either
AS+SP+PQ (single dose 0.75 mg/kg on the third treatment day,
nine sites) or AS+SP alone (12 sites) observed that PQ reduced the
gametocyte clearance time by 45% and the AUC of gametocyte
density over time (up to 28 days) by about the same proportion
(Shah 2013). They expressed the reduction as a hazard ratio with
PQ increasing the rate of gametocyte clearance by 1.9 (95% CI
1.1 to 1.3). These results are consistent with our findings. A pa-
per whose title implies it was a systematic review of the impact of
artemisinin derivatives and PQ on infectiousness, Abay 2013, in-
cluded only two before-and-after trials using PQ with small num-
bers of patients. Neither of these studies met our inclusion criteria
(Rieckmann 1968; Clyde 1971).
In a Cochrane Review of MDA (Poirot 2013), the authors found
no studies directly comparingMDA regimens that included 8AQs
with regimens that did not. In a secondary analysis, the authors
then subgrouped the included non-RCTs by regimens with and
without 8AQs. In high endemicity areas, two studies included
PQ, and one study did not. During multiple MDA rounds, there
were substantial drops in parasitaemia regardless of whether PQ
was included. At one to three months, the studies without PQ
showed larger impact than the one study that did, but this single
observation from a non-randomized comparison cannot be relied
upon. In a second similar subgroup analysis of four before-and-
after studies, the stratified analysis was uninformative.
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In an opinion piece in the Lancet, the possibility that doses lower
than 0.5 to 0.75 mg/kg might still be very effective in blocking
transmission is raised (White 2013). Based on the current review,
it appears that the effect on infectiousness and gametocytes is
preserved at lower doses of 0.2 to 0.25 mg/kg.
A review in theMalaria Journal provides an analysis of published
and unpublished data on 158 subjects with different drug expo-
sures spanning 80 years (White 2012). The methods, sources of
data and comparisons are not clearly specified, but the authors
argue this provides evidence that PQ decreases infectivity much
faster than the effect on gametocytes would suggest. The current
review supports this view that the effect of PQ on infectiousness
appears earlier (day 3-5) than the effect on gametocyte presence,
at least for artemisinin partners. However the effect on infectious-
ness wanes by day 8 due to declining infectiousness in both PQ
and control groups.
Also in the Malaria Journal, White 2014 urged stratification of
trials by dose, which has now been further accomplished with the
newly included trials at lower doses. The overall conclusion of
White 2014 endorses the conclusions of all earlier editions of this
Cochrane Review: there is a need for moremosquito-feeding stud-
ies for “the assessment of transmission-blocking, dose-response re-
lationships”. This updated review now includes several trials that
report reduction in infectiousness soon after treatment, and hence
improve on earlier recommendations based only on indirect mea-
sures. However, although there were five new trials aiming to study
infectiousness included here, all trials except two had no or very
few infection events. Overall infectiousness of patients attending
for malaria treatment is very low and wanes quickly, despite a large
proportion having PCR detectable gametocytes.
In relation to current WHO guidelines, evidence is available from
this systematic review to support the currently recommended 0.25
mg/kg dose as 1) effective in potentially reducing transmission
from individuals to mosquitoes and 2) probably safer than higher
doses for those without G6PD deficiency and possibly for those
with the deficiency. This review of all available evidence shedsmin-
imal light on the questionofwhether PQat any dosewillmaterially
affect transmission in communities (WHO 2012b;WHO2015b).
The amount of evidence on infectiousness of treated malaria pa-
tients to mosquitoes remains low, and evidence of the impact of
treating malaria patients on transmission at a community level
completely absent.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current policy recommendations are that 0.25 mg/kg PQ should
be added as a single dose to primary treatment for P. falciparum
malaria in areas of low transmission to reduce infectiousness of
treated individuals to mosquitoes, under the assumption that this
will contribute to reducing malaria prevalence.
This Cochrane Review of all reliable data supports the idea of re-
ducing infectiousness of people to mosquitoes, but provides very
little evidence on the question of whether this reduction is of any
material value in reducing community prevalence. It is consistent
with the recommendation that PQ not be used in high endemicity
areas, where the dilutional effects of a large part of the population
carrying asymptomatic infections would likely outweigh a poten-
tial benefit. In a low endemicity area, what might be important
is whether most people with parasitaemia are likely to be treated.
If PQ is used systematically, monitoring malaria prevalence in a
well-designed programmemight provide useful information on its
effectiveness.
If PQ is to be used, then it should be implemented as early as
possible during treatment as the effects on infectivity appear to be
maximal early in the treatment course.
Risk of harm at the currently recommended dose of 0.25 mg/kg
was low in the study participants, relatively few of whom were
G6PD-deficient. However, the emphasis in the included trials,
hence in this systematic review, is on the efficacy of PQ, and ev-
idence from these sources is insufficient to comment definitively
on safety in all affected populations.
Implications for research
The totality of the evidence from the trials included in this review
does not provide a clear answer about whether, or under what
circumstances, low-dose PQ could materially reduce the commu-
nity malaria burden. We do not envision direct evidence being
generated that will fill this high-level gap; to do so would require
many large cluster-randomized trials at different endemicity levels,
conducted over many years. A realistic approach would combine
evidence from randomized trials and possibly some observational
data in robust mathematical models to predict the impact of PQ
on malaria transmission at the community level across the range
of endemicity levels. This Cochrane Review is the first step toward
determining whether the existing information is sufficient to in-
form modelling studies and, if not, what specific questions must
be addressed in further field or laboratory research to generate ev-
idence that can be used for sound future recommendations.
A next step could be the collaborative evaluation of current evi-
dence by recent randomized trialists, mathematical modelers who
are working on this question, and others involved with malaria
control policy. It would be important to examine key parameter es-
timates (and the relevant variability in those parameter estimates)
in relation to the question of whether low-dose PQ should be im-
plemented in combination with antimalarial treatment of acute
episodes of malaria illness and, if yes, when and under what cir-
cumstances. A consensus could be reached about whether results
from additional trials would provide missing information. This
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determination would guide decisions on the need for further trials
and if needed, precisely what endpoints should be sought.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arango 2012
Methods Quasi-RCT: alternate allocation to AQ+SP and AQ+SP+PQ, then MQ+AS and
MQ+AS+PQ
Participants Inclusion criteria
• Uncomplicated malaria.
• P. falciparum only.
• Not pregnant.
• Voluntary consent.
Colombia
82 participants, aged one to 75 years (mean age ranged from 24 to 35 years in four
groups)
Gametocytes in 23/82 (28%)
Interventions All loose combinations
• AQ+SP.
• AQ+SP+PQ.
• MQ+AS.
• MQ+AS+PQ.
AQ: 25 mg/kg total dose divided into 10 mg/kg on day 1 and 7.5 mg/kg on days 2 and
3
SP: 25 mg/kg/1.25 mg/kg single dose on day 1
MQ: 25 mg/kg total dose, divided into 8.3 mg/kg per day for 3 days
AS: 4 mg/kg per day for 3 days
PQ: 0.75 mg/kg, total single dose on day 2
Outcomes Day 1 (pretreatment with schizonticide), 4 and 8
Asexual and gametocyte counts in thick smears
Gametocyte prevalence
Gametocyte density
Notes No mention of G6PD status
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternate allocation.
Allocation concealment (selection bias) Unclear risk Not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data.
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Arango 2012 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Unclear risk No information given.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not discussed.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not discussed.
Chen 1993a
Methods RCT
Participants 18 participants, healthy adults with P. falciparum and positive for gametocytes
Setting: China
Interventions A: MQ 750 mg.
B: MQ 750 mg + SP (1500 mg/75 mg).
C: MQ 750 mg + PQ 45 mg.
Follow-up: 28 days for gametocytes and 21 days for infectiousness
Outcomes Gametocyte prevalence at days 3, 8, 14, and 21
Infectiousness to An. dirus
Sporozoite infections in mosquitoes
Infectivity of sporozoite-infected mosquitoes to subsequent patients
Notes Only abstract available.
Mosquitoes fed on the patients were allowed to develop sporozoites which were then fed
on uninfected people. One of the MQ + PQ group passed the infection to a new person
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Trial authors stated it was randomized in abstract but no details
given in the text
Allocation concealment (selection bias) Low risk Supervisor who oversaw patients taking the drug opened a sealed
envelope then saying what drug it was
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were followed up.
Selective reporting (reporting bias) Unclear risk No information in the text.
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Chen 1993a (Continued)
Other bias Unclear risk No information given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double blind in the text.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information in the text.
Chen 1994
Methods Possibly individually RCT (stated to be randomized but no information given)
Dates of trial not reported.
Participants 27 participants with slide positive P. falciparum including both asexual stages and game-
tocytes. No information given on age or sex. All dosages appear to be adult dosages
Site: malaria-endemic Hainan Island, China.
Exclusion criteria: history of antimalarial treatment for present attack
Interventions • Artemisinin: 1200 mg per day for 5 days (not included in review).
• MQ 750 mg single dose day 1 (reported as day 0).
• MQ 750 mg single dose + PQ 45 mg single dose day 1 (reported as day 0).
Outcomes • Gametocyte density: days 5, 8, 15, 22, and 29 (reported in paper as days 4, 7, 14,
21, and 28 since first day was day 0). Given as % of initial density on chart only.
• Percentage of participants infectious to An. dirus: days 5, 8, 15, and 22 (reported
as days 4, 7, 14, and 21).
• Percentage of mosquitoes infected: days 5, 8, 15, and 22 (reported as days 4, 7,
14, and 21).
Notes For gametocyte density, graph only of percentages; no raw numbers given except range
of asexual and gametocyte numbers reported for each group on day 1 (reported as day
0)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on sequence generation.
Trial authors described process as partici-
pants “divided into groups A, B, and C”.
Equal number in each group and lack of
detail suggests randomization not done ad-
equately
Allocation concealment (selection bias) High risk No data to suggest any measures to conceal
allocation.
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Chen 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing participants in intervention
groups 2 and 3.
Selective reporting (reporting bias) Low risk No obvious selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Dicko 2016
Methods Individually RCT
Participants 81 men aged 5 to 50 years
All gametocyte carriers by microscopy (≥ 32 gametocytes/µL) - at least 2 gametocytes/
500 wbcs on thick film
Hb ≥ 8 g/dL
Normal G6PD by colorimetric classification
Oulessbougoue, near MRTC Mali
Exclusion criteria
• Malaria drugs in last 7 days.
• Known allergies to study drugs.
• Serious or chronic illness.
• Diagnosed cardiac arrhythmias.
Interventions DHAP daily for 3 days, by weight to closest whole tablet; tablets were 320 mg DHA
and 40 mg piperaquine
13 kg to < 24 kg: 1 tablet; 24 kg to < 36 kg: 2 tablets; 36 kg to < 75 kg: 3 tablets; 75 to
100 kg: 4 tablets
DHAP plus PQ on day 1 at 0.125 and 0.5 mg/kg in Phase 1
DHAP plus PQ on day 1 at 0.065 and 0.25 mg/kg in Phase 2
PQ dissolved in water and given orally, observed.
Outcomes People infective to mosquitoes on day 1 (pretreatment), 2, 3, and 8
Mosquitoes infected on day 1 (pretreatment), 2, 3, and 8 by membrane feeding
Mean within-person change in mosquito infectivity (in all participants, and only those
who were infectious on day 1)
Hb on day 1, 2, 3, 4, 8, 15, 29
Mean within-person change in Hb after treatment on day 1, 2, 3, 4, 8, 15, 29
Adverse events (mild, moderate, severe) on day 2, 3, 4, 8, 15, 29
Gametocyte prevalence and density by microscopy day 1 (pretreatment), 2 hours, 6
hours, 12 hours, and days 2, 3, 4, 8, 15, 29
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Dicko 2016 (Continued)
Gametocyte prevalence and density by qRT-PCR, same time points
CYP2Dˆ genotype and metabolizers phenotype
AUC gametocyte density (qt-PCR) over time to day 29
Notes Study was halted after 8 participants enrolled in phase 1, due to low infection rate in
mosquitoes before treatment. Protocols were optimized and the study restarted 6months
later
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study was in two phases: phase 1 was RCT (in blocks of 6) and
phase 2 was not randomized (alternate allocation?)
Allocation concealment (selection bias) High risk Sealed opaque envelopes in phase 1. In phase 2 “participants
were enrolled first into 0.25 mg/kg group and then 0.0625 mg/
kg group when full”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 79/81 (97.5%) had at least one follow-up visit; 68/81 (84%)
completed all follow-up to day 29
Selective reporting (reporting bias) Unclear risk Gametocyte density by microscopy is not reported except at
baseline and in summary form for intervention and control
groups combined at day 3 and 8 in the discussion
Other bias Low risk None known.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Study participants were allowed to ask which group theywere in.
PQ taste is distinctive. Unlikely that participants knowledge of
their status could influence infectivity or gametocyte prevalence
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigators and outcome assessors were blinded.
El-Sayed 2007
Methods Individually RCT
Dates of trial: randomization June 2004; trial done 17 August 2004 to 3 September
2004
Participants 104peoplewith asymptomaticP. falciparumpositive by slide andpositive for gametocytes
by PCR. No information given on age and sex
Site: 2 villages in East Sudan where there is seasonal malaria, mainly P. falciparum, during
October to December.
Exclusion criteria: pregnancy, history of sulfa allergy, fever or other symptoms, Plasmod-
ium spp other than P. falciparum present.
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El-Sayed 2007 (Continued)
Interventions • AS: children < 50 kg: 4 mg/kg; all > 50 kg: 200 mg (two 100 mg tabs) days 1, 2,
and 3 (reported as days 0, 1, and 2). SP: children < 50 kg: 25 mg/kg S + 1.25 mg/kg P;
All > 50 kg: 3 tablets of 500 mg S + 25 mg P.
• As for 1. above plus PQ 0.75 mg/kg day 4 (reported as day 3).
Outcomes • Proportion of people with P. falciparum parasites by PCR days 4, 8 and 15
(reported as days 3, 7, and 14).
• Proportion of people with gametocytes by RT-PCR days 8 and 15 (reported as
days 7 and 14).
• Adverse events days 2, 3, 4, 8 and 15 (reported as days 1, 2, 3, 7, and 14).
• Packed cell volume days 1, 8 and 15 (reported as days 0, 7, and 14).
Notes The trial was conducted about twomonths after the initial screening for positives (asymp-
tomatic carriers)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The list of carriers was sorted according
to village and age to ensure that the treat-
ment groups were balanced with respect to
these two variables. The random allocation
of this ordered list into the treatment arms
was then created using restricted random-
ization with a block size of 12 in STATA
v7”
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 3/104 participants did not complete
follow-up.
Selective reporting (reporting bias) Low risk No obvious selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients and health staff were not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory staff doing PCR were blinded.
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Eziefula 2013
Methods Individually randomized placebo-controlled, double blind trial conducted December
2011 to March 2013
Participants 468 randomized, aged one to 10 years old, male and female
Setting: Uganda
Inclusion criteria
• P. falciparum mono infection with parasite density lower than 500,000 parasites/
µL
• Normal G6PD enzyme function
• Fever or history of fever in past 24 hours
Exclusion criteria
• Signs of severity.
• Haemoglobin concentration < 80 g/L.
• Known allergy to the trial drugs.
• Antimalarials taken within the past 2 days.
• PQ taken within the past 4 weeks.
• Blood transfusion within the past 90 days.
Interventions • AL standard three day (twice per day) course + placebo (given with 5th AL dose,
that is, with 1st dose on 3rd day of treatment).
• AL + 0.1 mg/kg PQ.
• AL + 0.4 mg/kg PQ.
• AL + 0.75 mg/kg PQ (reference).
Outcomes Primary efficacy: mean duration of gametocyte carriage
Secondary efficacy: point prevalence of gametocytes on days 7, 10 and 14; gametocyte
circulation time (days), AUC of gametocyte density
Primary safety: arithmetic mean maximum decrease in haemoglobin concentration from
enrolment to day 28
Secondary safety: day of haemoglobin nadir, maximum percentage decrease in haemo-
globin, percentage of participants with haemoglobin concentration lower than 50 g/
L, requirement for blood transfusion, evidence of black urine, and frequency of severe
adverse events
Mean absolute and relative change in Hb on day 3, 7, 10 stratified by G6PD status
Gametocyte prevalence on day 7 stratified by CYP2D6 metabolism status
Notes G6PD enzyme function based on a fluorescence spot test (R&D Diagnostics, Aghia
Paraskevi,Greece) andongenotyping ofG6PDA-; 202A and376G.CYP2D6genotyped
by QuantSudio 12K Flex system and 32SNP Open Array and Copy number variation
assays (N = 247)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated 4-digit treatment as-
signment codes and allocated these to ran-
dom dose groups in block sizes of 16
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Eziefula 2013 (Continued)
Allocation concealment (selection bias) Low risk Only the pharmacist was aware of alloca-
tion.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 8%of participantswere lost to follow-
up. No group significantly different from
others
Selective reporting (reporting bias) Low risk None detected or suspected.
Other bias Low risk None detected or suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Masking syrup” added to all treatments to
mask taste of drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded.
Gogtay 2004
Methods Allocated by “simple, computer-generated randomization code”
Participants Twenty-two patients in Mumbai, India
Inclusion criteria
• > 18 years.
• Normal G6PD.
• > 55 P. falciparum gametocytes/µL on admission.
Exclusion criteria
• Complicated malaria.
Interventions • Quinine days 1 to 7: 30 mg/kg/day + PQ (45 mg).
• Quinine days 1 to 7: 30 mg/kg/day + bulaquine (approximately 75 mg base).
Outcomes Asexual and gametocyte counts on days 1, 4, 8, 15, 22, and 29
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization.
Allocation concealment (selection bias) Unclear risk Not reported.
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Gogtay 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk Unbalanced allocation (9 versus 13) and
small number of participants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory technician reading blood
smears was blinded.
Gogtay 2006
Methods Randomized (computer-generated) to PQ or bulaquine (1:2 ratio) after primary treat-
ment with quinine + doxycycline
Participants 93 participants in India
Inclusion criteria
• > 16 years.
• Male.
• Uncomplicated P. falciparum only.
• > 55 P. falciparum gametocytes/µL on admission.
Exclusion criteria
• Antimalarial treatment in previous two weeks.
• Allergy to trial drug.
• G6PD deficient.
Interventions All patients: quinine days 1 to 7: 30 mg/kg/day (10 mg/kg/day three times per day) +
100 mg doxycycline
Randomization and treatment on day 4
• PQ.
• Bulaquine.
Outcomes Gametocyte prevalence, density and viability on days 1, 4, 15, 22, and 29
Adverse events
Notes Gametocyte viability assessed by Shute’s technique (ex flagellation)
Risk of bias
Bias Authors’ judgement Support for judgement
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Gogtay 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated randomization.
Allocation concealment (selection bias) Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data. Three par-
ticipants (2 bulaquine, 1 PQ) did not re-
turn for follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Slide readers were blinded.
Gonçalves 2016a
Methods Individually RCT. This is Phase 1 of the trial.
Participants Children aged 2 to 15 years
Asymptomatic
Normal G6PD by BinaxNOW RDT
Carrying patent P. falciparum asexual parasites or gametocytes (1000 to 200,000 para-
sites/µl)
Weigh ≥ 10 kg
Living in Balonghin, Sapone, Burkina Faso, an area of seasonal malaria transmission
Exclusion criteria: Hb < 8 g/dL, fever or history or fever in last 24 hours, antimalarials in
last 48 hours, PQ use in last 4 weeks, blood transfusion in last 90 days, non-P. falciparum
infection at screening.
Interventions AL: half a tablet (20 mg artemether and 120 mg of lumfantrine) per 5 kg body weight
in 6 doses over 3 days + placebo
AL+PQ: 0.25 and 0.4 mg/kg given on day 3 with the 5th dose of AL
Outcomes Gametocyte clearance time
Gametocyte prevalence by microscopy days 4, 8, 11, and 15
Proportion of mosquitoes infected
Oocyst counts
Max fall in Hb during follow-up (to day 15)
Number of participants needing blood transfusion
Max % decrease in Hb
Proportion of participants with Hb below 5 g/dL
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Gonçalves 2016a (Continued)
Serious adverse events
Notes Phase 1: children who are asymptomatic P. falciparum carriers (Gonçalves 2016a): N =
210
Phase 1: children who infect mosquitoes: no baseline feeding experiments
Confirmed P. falciparum gametocyte carriers in Phase 2 (Gonçalves 2016b): N = 150
Phase 2: children who infected mosquitoes: 30/79 38%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RCT stratified by gender and blocks of 6
(3 study arms and two feeding schedules)
Allocation concealment (selection bias) Low risk Sealed envelopes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Phase 1: 205/210 (97.6%) completed fol-
low-up to day 14.
Selective reporting (reporting bias) Low risk All prespecified outcomes appear to have
been reported.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo controlled; syrup was added to
mask taste of PQ.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Participants, investigators and staff were
blinded to study arm allocation”
Gonçalves 2016b
Methods Individually RCT. This is Phase 2 of the trial where inclusion criteria were modified to
increase probability of infecting mosquitoes
Participants Children aged 2 to 15 years
Asymptomatic
Normal G6PD by BinaxNOW RDT
Carrying patent P.falciparum gametocytes (1000 to 200,000 parasites/µl)
Weigh ≥ 10 kg
Living in Balonghin, Sapone, Burkina Faso, an area of seasonal malaria transmission
Exclusion criteria: Hb < 8 g/dL, fever or history or fever in last 24 hours, antimalarials in
last 48 hours, PQ use in last 4 weeks, blood transfusion in last 90 days, non-P. falciparum
infection at screening.
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Gonçalves 2016b (Continued)
Interventions AL: half a tablet (20 mg artemether and 120 mg of lumfantrine) per 5 kg body weight
in 6 doses over 3 days + placebo
AL+PQ: 0.25 and 0.4 mg/kg given on day 3 with the 5th dose of AL
Outcomes Gametocyte clearance time
Gametocyte prevalence by microscopy days 4, 8, 11, and 15
Proportion of mosquitoes infected
Oocyst counts
Max fall in Hb during follow-up (to day 15)
Number of participants needing blood transfusion
Max % decrease in Hb
Proportion of participants with Hb below 5 g/dL
Serious adverse events
Notes Asymptomatic P. falciparum carriers in Phase 1 (Gonçalves 2016a): N = 210
Confirmed P. falciparum gametocyte carriers in Phase 2 (Gonçalves 2016b): N = 150
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk RCT stratified by gender and blocks of 6
(3 study arms and two feeding schedules)
Allocation concealment (selection bias) Low risk Sealed envelopes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Phase 2: 146/150 (97.3%) completed fol-
low-up to day 14.
Selective reporting (reporting bias) Low risk All prespecified outcomes appear to have
been reported.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo controlled; syrup was added to
mask taste of PQ.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Participants, investigators and staff were
blinded to study arm allocation”
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Kamtekar 2004
Methods Individually RCT, comprising two distinct comparisons a: (CQ or [CQ+SP]) with and
without PQ and b: QN with and without PQ
Dates of trial: not given.
Participants 57 people aged≥ 16 years with symptomatic uncomplicated and 46 with severe (WHO
criteria) P. falciparummalaria, diagnosed by thick and thin blood slides. Gametocytaemic
within first 72 hrs with > 55 P. falciparum gametocytes/µL
Site: urban areas of Mumbai, India.
Exclusion criteria: pregnant or lactating, treatment for malaria within last 2 weeks, co-
infection with P. vivax, history of PQ allergy.
Interventions Comparison a: for uncomplicated malaria
All received CQ (some also got SP)
Day 4: randomized to PQ or placebo (45 mg)
Comparison b: for severe malaria
All received quinine
Day 8: randomized to PQ or placebo (dose 45 mg)
Doses background drugs: CQ 10 mg/kg on days 1 and 2; 5 mg/kg on day 3; SP 1500
mg; quinine dose 10 mg/kg every 8 hrs for 24 to 48 hrs and orally for total of 7 days
Outcomes • Proportion of people with gametocytes, days 1, 4, 8, 15, 22, and 29.
• Proportion of people with viable gametocytes (exflagellation), days 1, 4, 8, 15, 22,
and 29.
• Gametocyte density (given as range) days 1, 4, 8, 15, 22, and 29.
Notes No screening for G6PD deficiency. It is not stated how many got SP in addition to CQ
or why
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “simple computer generated randomiza-
tion code”.
Not all patients had gametocytes on day 1.
Inclusion criteria were that the person had
to have gametocytes in the first 72 hours
(from day 1?). This suggests some post ran-
domization inclusions or exclusions
Allocation concealment (selection bias) Unclear risk No information.
Incomplete outcome data (attrition bias)
All outcomes
High risk Originally there were 57 people included
inuncomplicated comparison (a), ofwhom
2 were lost to follow-up and 9 were not
evaluated as they showed CQ resistance
There were 46 in severe comparison (b), of
whom 3 were lost to follow-up
The final numbers evaluated in each group
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Kamtekar 2004 (Continued)
were (a) 22 and 24 (b) 22 and 21
Selective reporting (reporting bias) Unclear risk No obvious selective reporting.
Other bias High risk It was not clear why some patients got SP
and others did not, and the numbers in
each group are not given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial used a placebo for PQ. Patients and
health workers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Slide readers were blinded.
Khoo 1981
Methods Individually RCT
Dates of trial: between June 1976 and March 1978.
Participants 69 people (adults and children of both sexes, no ages specified) with G6PD deficiency
(full or partial by Brewer’s methaemoglobin reduction test) who were slide positive for
malaria (P. falciparum, P. vivax or mixed).
Site: Sabah, Malaysia.
Exclusion criteria: other associated clinical conditions.
Interventions • CQ: 1.5 g CQ over 3 days for P. falciparum, P. vivax or mixed, less for children.
• CQ + PQ: CQ as above plus 75 mg PQ over 3 days for P. falciparum; 210 mg PQ
over 14 days for P. vivax and mixed infections; less for children.
• SP (not included in this review): 1.5 g S and 75 mg P, single dose.
Outcomes • Haemolysis.
• Proportion cleared parasites by 72 hours.
• Need for blood transfusion.
• Renal failure.
Notes The participants are not divided by P. falciparum, P. vivax, or mixed, so it is not possible
to use the data.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “those found G6PD deficient were ran-
domly assigned”.
Allocation concealment (selection bias) Unclear risk No information given.
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Khoo 1981 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information given.
Selective reporting (reporting bias) Low risk No apparent selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Kolaczinski 2012
Methods Individually RCT
Dates of trial: between July and January, from 2000 to 2003.
Participants 237 individuals aged from 3 to 70 years, in 5 villages for Afghan refugees in Pakistan
Inclusion: > 2 years of age, P. falciparum mono-infection, confirmed by slide, will be
resident during entire follow-up period
Exclusions: pregnancy, signs of severe malaria, report of antimalarial drug in past 21
days, other serious disease
Interventions • CQ: 3 days 25 mg/kg.
• CQ+PQ: CQ as in 1; PQ on day 3 (0.5 mg/kg).
• SP: 25(S)/1.25(P) mg/kg in single dose.
• SP+PQ: SP as in 3; PQ on same day (0.5 mg/kg).
Outcomes • Clinical treatment failure (PCR non-adjusted and adjusted).
• Gametocytes on day 8.
• Gametocyte density on days 1 to 8 of follow-up.
• Genotyping of resistant strains for CQ and SP-specific mutations.
Notes Also included CQ + AS and SP + AS arms, compared with CQ ± PQ and SP ± PQ arms,
respectively
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients numbered sequentially at enrol-
ment. Randomnumberswith treatment as-
signment from Excel-generated lists, then
paired with patient numbers
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Allocation concealment (selection bias) Low risk Patient number concealed until after enrol-
ment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 209 of 237 randomized completed treat-
ment and at least one follow-up test. 47
(13%) of those randomized did not con-
tribute data. Variable numbers tested dur-
ing follow-up (see analyses)
Selective reporting (reporting bias) Low risk None detected.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Identified in report as “single-blind”. Man-
ager (gave Rx) not blinded; patients, mi-
croscopists and health workers “partially
blinded” due to different drug appearance
and times of follow-up. No placebos used,
but vitamin given to those in non-PQ arms
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Implied only.
Lederman 2006
Methods Individually RCT
Date of trial: July to Oct 2001.
Participants 117 malaria cases with P. falciparum ≥ 400 asexual stages/µL (thick film) recruited by
mass blood survey and passive case detection. Symptoms not required
Age: ≥ 15 years
Site: Central Java, Indonesia, an area with high CQ resistance and resurgent malaria
approximately equal P. falciparum and P. vivax.
Exclusion criteria: Pregnancy, breast feeding, body weight < 40 kg, G6PD deficiency,
history of antimalarial or antibiotic in last 7 days, severe or complicated malaria, history
or allergy or adverse reaction to trial medications, P. vivax or mixed infection.
Interventions • CQ only (not included in this review).
• CQ+SP: CQ 150 mg base, 10, 10 and 5 mg/kg on days 1, 2, 3 (reported as days
0, 1, 2). SP 500 mg S 25 mg P on day 1 (reported as day 0).
• CQ+SP as for group 2 above plus PQ 45 mg on day 1 (reported as day 0).
• CQ+SP as for group 2 above plus PQ 45 mg on day 3 (reported as day 2).
Outcomes • Parasite clearance time assessed at days 1, 3, 8, 15, 22, 29 or day of recurrent
parasitaemia (reported as days 0, 2, 7, 14, 21, 28)
• Fever clearance time at days 2, 3, 4, 5, 8, 12, 15, 19, 22, 29
• Proportion of people with gametocytes (from chart) days 1 to 29
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• Adverse events
Notes Some comparisons in the results reported include the CQ only group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Trial subject codes were assigned to treat-
ment arms by a random process (not spec-
ified)
Allocation concealment (selection bias) High risk Eligibles were assigned a sequential par-
ticipant number by the screening physi-
cian. Pre-packaged treatment but not stated
whether allocation was concealed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7%of participants withdrew before day 28.
Selective reporting (reporting bias) Unclear risk Abstract states that drugs were well toler-
ated and safe but no evidence is given in
report
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was implied only.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding was implied only.
Lin 2017
Methods Individually RCT
Participants 101 adults aged 18 to 65 years, 97% male presenting or referred with uncomplicated
P. falciparum or mixed P. falciparum/P. vivax infection diagnosed with microscopy and
confirmed with qPCR, had mild or moderate G6PD deficiency
Setting: Cambodia
Interventions DHAP: daily for 3 days; tablets containing 40mg DHA and 320 mg piperaquine each
PQ: single dose 45mg at day 3
Outcomes The proportion of individuals infecting at least 1 mosquito out of 50, at 1 and 2 weeks
post-treatment in the 2 arms
The effect of the 2 treatment regimens on the risk of gametocyte carriage as measured
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by microscopy and RT-PCR. This was done by comparing gametocyte prevalence at
weekly timepoints post-treatment and the time to gametocyte clearance in the 2 arms
The number of infected mosquitos per treatment arm, the relationship of gametocy-
taemia to mosquito infectivity, and within-person changes in haemoglobin 4 days post-
PQ treatment among volunteers with G6PD-deficiency
Notes Baseline infectivity of participants (day 0): DHAP 6/51 (12%); DHAP+PQ 1/51 (2%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block size 2, randomization scheme and codes prepared in ad-
vance
Allocation concealment (selection bias) Low risk Sealed envelopes offered to patients to choose from.
Incomplete outcome data (attrition bias)
All outcomes
Low risk less than 10% loss to follow-up by day 8; >10% at day 15.
Selective reporting (reporting bias) Low risk Not detected.
Other bias Unclear risk Baseline infectivity between the groups probably chance.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Mwaiswelo 2016
Methods Individually RCT
Participants Yombo primary health facility, Bagamoyo town, an area of high year round transmission
in Tanzania with two seasonal peaks
220 participants
Inclusion criteria
• Gender: both.
• Age of 1 year and above and neither pregnant nor breast feeding.
• Weight over 10 kg.
• Body temperature = 37.5°C or history of fever in the last 24 hours.
• P. falciparum mono-infection.
Exclusion criteria
• Evidence of severe illness malaria or danger signs.
• Known allergy to study medications.
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• Haemoglobin < 8 g/dL.
• Antimalarials taken within last 2 weeks.
• Blood transfusion within last 90 days and evidence of recent use (within 14 days)
of or will be taking other drugs known to cause haemolysis in G6PD-deficient subjects.
Interventions AL standard doses by weight, six doses over 3 days. Placebo given with dose 1
AL+PQ (0.25 mg/kg) with dose 1, thereafter AL only.
Outcomes No gametocyte outcomes were reported. Original planned outcomes:
Primary outcome planned: number of days per treatment arm for gametocytes to become
undetectable using quantitative nucleic acid sequence based assay (QT-NASBA) (time
frame: 14 days)
Secondary outcome:meanmaximal fall in haemoglobin (g/dL) from enrolment to day 28
of follow-up defined as mean greatest negative difference in haemoglobin per treatment
arm (time frame: 28 days)
Actually reported: PCR-adjusted asexual parasite outcomes (parasitological cure)
Mean relative reduction in Hb between day 1 and 8
Notes ClinicalTrials.gov identifier: NCT02090036
Primary sponsor: Muhimbili University of Health and Allied Sciences
Secondary sponsor: Karolinska Institutet
Patients were admitted during treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sex-stratified block randomization with 4 blocks, 2 per treat-
ment arm using Research Randomizer v4
Allocation concealment (selection bias) Low risk Opaque envelopes with pre-determined treatment codes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 211 out of 220 (95.9%) completed the follow-up.
Selective reporting (reporting bias) High risk Trial was designed to look at gametocyte clearance but this was
not reported because only one enrolled patient had gametocytes
at baseline
Other bias Low risk None known.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single blind. Nurses giving treatment opened the envelopes. Pa-
tients were blinded but could have noticed extra tablet. Glucose
syrup masked the taste
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
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Okebe 2016
Methods Individual RCT
Participants 694 asymptomatic malaria-infected (RDT, then microscopy, > 20 parasites/µl) G6PD
normal individuals aged ≥ 1 year
Upper and Central River Regions, The Gambia, in an area with seasonal transmission
peaking between Sept and Nov
Age ≥ 1 year and weight > 10 kg
G6PD normal
Hb > 8 g/dL
No known allergy to study drugs
Not pregnant or breastfeeding
No malaria treatment in last 2 weeks
No blood transfusion in last 3 months
No history of sickle cell anaemia
No chronic or acute conditions that might interfere with the study
170 participants in membrane feeding studies.
Interventions • DHAP only.
• DHAP 3 days + 0.2 mg/kg PQ on day 3 (reported as 2).
• DHAP 3 days + 0.4 mg/kg PQ on day 3 (reported as 2).
• DHAP 3 days + 0.75 mg/kg PQ on day 3 (reported as 2).
Outcomes Participants with gametocytes on day 1, 4, 8, 11, 15 (reported as 0, 3, 7, 10, 14) by QT-
NASBA
Participants infectious to mosquitoes on day 8 (reported as 7)
Mosquitoes infected on day 8 (reported as 7)
Adverse events
Clinical follow-up to day 43
Notes ClinicalTrials.gov NCT01838902
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization list generated by the trial statistician using
STATA 13. 1:1:1:1 ratio using blocks of varying size to ensure
a balance between the 4 groups. A separate randomization se-
quence was used to select participants for membrane feeding
Allocation concealment (selection bias) Low risk Sequentially numbered opaque envelopes prepared from ran-
domization list by non-study physician
Incomplete outcome data (attrition bias)
All outcomes
Low risk 647/694 (93.2%) of participants completed follow-up.
Selective reporting (reporting bias) Low risk Not detected.
Other bias Low risk Not detected.
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label: staff involved in clinical care including the trial drugs
were aware of assigned groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Those involved in sample processing and data analysis are
blinded
Pukrittayakamee 2004
Methods Individually RCT
Dates of trial not stated.
Participants 176 patients with acute uncomplicated P. falciparum. After exclusion of QN+tetracycline
group: 146.
Age 14 to 62.
All male.
Site: Hospital for Tropical Diseases, Bangkok, Thailand.
Exclusion criteria: severe malaria, mixed malaria infection, history of drug hypersensi-
tivity, any antimalarial within last 48 hrs, urine positive for sulfonamide or 4AQ
People with G6PD deficient phenotype were excluded from receiving PQ
Interventions • QN: QN sulfate (300 mg salt/tab) at 10 mg salt/kg, three times per day for 7 days.
• QN+tetracycline (excluded from this review).
• QN+PQ low dose: QN as above in 1 plus PQ 15 mg base/tab, 0.25 mg/kg base
(adult dose 15 mg base) daily for 7 days.
• QN+PQ high dose: QN as above in 1 plus PQ 0.50 mg/kg base (adult dose 30
mg base) daily for 7 days.
• AS: AS 50 mg salt/tab 3.3 mg/kg (adult dose 200 mg) on day 1 and 1.65 mg/kg
(adult dose 100 mg) daily on days 2 to 7.
• AS+PQ (high dose): AS as above plus PQ 0.5 mg/kg base daily on days 1 to 7.
Outcomes • Parasite clearance time: measured at 12 hrs until clearance.
• Gametocyte clearance time: median, 12 hrs until clearance.
• Fever clearance time (measured every 4 hr at first and then every 6 to 12 hrs until
resolution of fever).
• Parasite reduction ratio at 48 hrs.
• Reappearance of infection P. falciparum/P. vivax up to 28 days.
• Prevalence of gametocytes on admission/after treatment/total.
• Gametocyte carriage: total number of hours for which gametocytes were
detectable.
Notes Patients with recrudescence of P. falciparum or relapse of P. vivax were re-treated with 7
day QN+tetracycline or ‘standard doses’ of CQ+PQ respectively; not clear if they were
excluded from further trial
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Method not stated. Patients with G6PD
deficiency were excluded from getting PQ
which suggests randomization was biased
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 122/142 of the original participants in the
5 groups studied here completed follow-
up. Patients with recrudescences of P. falci-
parum or relapse of P. vivax were re-treated
with QN+tetracycline or CQ+PQ respec-
tively; not clear if they were excluded from
further trial
Selective reporting (reporting bias) Unclear risk Not detected.
Other bias Unclear risk Those who were unable to stay in hospital
until clearance of both fever and parasites
were excluded from trial of fever clearance
time
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Shekalaghe 2007
Methods Individually RCT
Dates of trial: June to Sept 2006.
Participants 108 children with fever > 37.5°C or history of fever in last 48 hours and P. falciparum
mono-infection 500 to 100,000/µL.
Age three to 15 years.
Both sexes.
Site: Mynuzi health centre, North-Eastern Tanzania, a hyperendemic area with rainy
seasons in March to June and October to December
Exclusion criteria: Hb < 8, inability to take drugs orally, known hypersensitivity to meds,
reported anti-malarial treatment in last 2 weeks, evidence of chronic disease or acute
infection other than malaria, domicile outside trial area, signs of severe malaria, eligible
for other malaria studies
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Interventions • AS+SP: AS: 4 mg/kg once daily for 3 days; SP: S 25 mg/kg and P: 1.125 mg/kg.
• AS+SP+PQ: As above for AS and SP plus PQ base 0.75 mg/kg on the third day.
Outcomes • Proportion of people with gametocytes (by microscopy) days 1, 4, 8, 15, 29 and
43 (reported as 0, 3, 7, 14, 28, and 42).
• Proportion with gametocytes (by PCR), same time points.
• Gametocyte density by PCR.
• AUC for gametocyte presence.
• Adverse events.
• Adequate clinical and parasitological response.
• Haemoglobin.
Notes Hb outcome assessed with respect to G6PD variant.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated in STATA 8.0 using restricted
randomization with block size of 20
Allocation concealment (selection bias) Low risk Pre-prepared envelopes (but person who
opened envelope administered treatment)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 out of 108 failed to complete fol-
low-up.
Selective reporting (reporting bias) Low risk No information given.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trial physician evaluated patients, opened
envelopes, and administered treatment.
Other staff were blinded. Not clear if par-
ticipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Singhasivanon 1994
Methods Individual RCT
Dates of trial: not stated.
Participants 23 people with uncomplicated P. falciparum malaria, parasitaemia between 1 to 5 per
1000 RBC.
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Age 5 to 12 years, sex not stated.
Exclusion criteria: antimalarial drugs, urine with quinoline and sulfonamide drugs, other
diseases, hematocrit ≤ 20%, inability to take oral medication
Interventions • MSP: MQ 20 mg/kg; S 40 mg base/kg; P 2 mg/kg; single dose.
• MSP + PQ: As above plus PQ 0.75 mg/kg single dose. MSP+PQ crushed and
mixed with 30 mL syrup (83% dextrose).
Outcomes • Gametocyte clearance time (days) (assessed twice daily until negative, then once
daily, by blood slide).
• Adverse drug reactions, assessed once daily in first week then once a week.
• Parasite clearance time (hrs).
• Fever clearance time (hrs).
• Cure rate.
Notes Those who vomited within 3 hours of Rx were excluded - this is a post-randomization
exclusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information given.
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcomes only reported for 18 of the 23
participants.
Selective reporting (reporting bias) Unclear risk No information given.
Other bias High risk Those who vomited within 3 hours of Rx
were excluded; this is a post-randomization
exclusion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
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Methods Individually RCT (5 comparisons, 10 arms).
Follow-up: patients were asked to return weekly for 9 weeks for assessment and at any
other time they were unwell
Dates: December 2008 to March 2009.
Participants Number: 808 people attending clinics in Myanmar.
Inclusion criteria: age > 6 months, weight > 5 kg, P. falciparum mono-infection 500 to
200,000 parasites/µL or co-infection with P. vivax, informed consent.
Exclusion criteria: pregnancy, signs of severe malaria, severe malnutrition, history of
hypersensitivity to any of the trial drugs, severe malnutrition, concomitant febrile illness,
history of psychiatric disorder, a full course of MQ in the previous 9 weeks or any other
antimalarial in the previous 48 hrs
Interventions Each of the five trial arms was divided into two where one half also received a one-off
dose of 0.75 mg/kg PQ on day 1
Groups:
1+2. AS plus amodiaquine, fixed-dose combination: 25 mg/67.5 mg or 50 mg/135 mg
or 100 mg/270 mg tablets
• AS 4 mg/kg once daily for 3 days
• AQ 10.8 mg base/kg once daily for 3 days
3+4. AL, fixed-dose combination: 20 mg/120 mg tablets.
• A 3.3 mg/kg in two divided doses each day for 3 days
• L 19.8 mg/kg in two divided doses each day for 3 days
• Advised to consume fatty food or breast feed before each dose
5+6. AS plus MQ, fixed-dose combination: 25 mg/55 mg or 100 mg/220 mg tablets
(artesunate: Guilin, Lariam: Hoffman-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 8.8 mg/kg once daily for 3 days
7+8. Artesunate plus MQ, loose combination (artesunate: Guilin, Lariam: Hoffman-La
Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 1 (reported as day 0)
9+10.DHAP, fixed-dose combination: 40mg/320mg or 20mg/160mg tablets (Artekin:
Holleykin)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
First dose supervised, all others unsupervised.
Outcomes • Recurrent parasitaemia at day 15, 29, 43 and 64 (reported as days 14, 28, 42, and
63).
• Treatment failure due to P. falciparum.
• Gametocytaemia prevalence.
• Person-gametocyte weeks.
• Haemoglobin on days 1 and 64.
• Adverse events (monitoring not described).
Notes Funding: Médecins sans Frontières (Holland).
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “After patients were screened and enrolled
in the study, they were stratified prospec-
tively into three age groups (1 to 4 years,
5 to 14 years and older than 14 years).
Patients were randomly assigned in equal
numbers to receive one of the five different
treatments. They were then randomly as-
signed either a single dose of PQ ...or not”
Allocation concealment (selection bias) Low risk “Treatment allocations were put in sealed
envelopes in blocks of 50 for each
age group, and random assignment was
achieved by patients drawing an envelope
from a box after enrolment. When the
box was empty, another 50 envelopes were
added”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition is low in absolute numbers and
unlikely to have introduced significant bias
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial for patients and medical
staff.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Microscopists were blinded.
Sutanto 2013
Methods Two-arm open-label RCT
Follow-up: days 1, 2, 3, 7, 14, 21, 28, 35, and 42, and any other day in between if they
felt ill. Thin and thick blood smears and dried blood spot for genotyping
Dates of randomization: December 2008 to March 2010
Participants 188 (178 left on day 3) + 186 (171 day 3). Analysis based on those still present on day 3
Setting: Hanura Primary Health Center, Padang Cermin district, Lampung province
located at the southern end of Sumatra
Endemicity: low malaria endemicity with a malaria prevalence of 1.8% across all age
groups. Seasonal transmission
Inclusion criteria
• Parasite density ≥ 1000 parasites/µL.
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• Age ≥ 5 years.
• Normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels based on a
qualitative test.
• Haemoglobin level ≥ 8 g/dL.
• Negative pregnancy test (assessed by human chorionic gonadotropin urine test) or
not breastfeeding.
• No signs of severe malnutrition.
• No other chronic diseases.
• No history of allergy to the trial drugs.
• Ability to return for 42 days of follow-up.
Interventions • Standard 3-day DHAP (fixed-dose tablets of 40 mg dihydroartemisinin and 320
mg piperaquine; D-ARTEPP, Guilin Pharmaceutical Co, Ltd).
• DHAP as in intervention 1; PQ: Day 3, single dose of 0.75 mg/kg, rounded to
the nearest half tablet. Mean dose was 0.74 mg/kg (range, 0.5 to 0.94 mg/kg).
Outcomes • Gametocyte prevalence-days 7, 14, 21, 28, 35, and 42.
• Gametocyte clearance rates by day 42 in patients with gametocytes on day 3.
• Recurrence of asexual stages of P. falciparum, PCR adjusted and unadjusted for
reinfections.
• Gametocyte development by day 42 in patients who were gametocyte free on day
3.
• Gametocyte densities between days 3 and 42 inclusive.
• Asexual infection recurrence by PCR.
• Haemoglobin on days 7, 42.
• Adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequences in blocks
of 4.
Allocation concealment (selection bias) Low risk Opaque envelopes used in order at the
health centre.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of differential attrition.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None detected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, no PQ placebo.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information.
Tine 2017
Methods Individually RCT
Participants Adult patients > 18 years of age presenting with falciparummalaria with a parasite density
of 1000 to 100,000 trophozoites/µL
Setting: Senegal, Deggo health post, Pikine, Dakar
Number of participants: 274 randomized (over two transmission seasons)
Exclusion criteria
• Pregnant (confirmed by urine testing).
• Breastfeeding.
• History of hypersensitivity to any of the study drugs.
• Severe malaria.
• Moderately severe anaemia (haemoglobin < 8 g/dL).
• Had a chronic illness.
Interventions • AL: twice daily; tablets containing 20 mg artemether and 120 mg lumefantrine.
• DHAP: daily for 3 days; tablets containing 40 mg DHA and 320 mg piperaquine.
• ASAQ: daily for 3 days, 2 tablets containing 100 mg artesunate plus 270 mg
amodiaquine.
• PQ: single dose 15mg given on the first day of treatment with the ACT in the
intervention arm.
• PQ +AL was given with biscuits.
Outcomes • Change in Hb from day 0 to day 7.
• Change in Hb by day 3, day 14, day 21, and day 28.
• Anaemia (Hb < 11 g/dL) at any time up to day 28.
• Clinical adverse events up to day 28.
• Prevalence and density of gametocyte carriage during follow-up.
Notes Patients were withdrawn from the study and treated with quinine if they vomited for a
second time within 30 minutes of taking each treatment dose
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization of 18, to 6 treatment groups.
Allocation concealment (selection bias) Low risk Numbered sealed opaque envelopes opened by study pharmacist
at time of treatment
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 4% loss to follow-up.
Selective reporting (reporting bias) Low risk None detected.
Other bias Low risk None detected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial assessors not blinded, although microscopists and labora-
tory technicians were not aware of allocation
Vásquez 2009
Methods Individually RCT
Dates of trial: April 2007 to Feb 2008.
Participants 50 people with uncomplicated P. falciparum diagnosis by thick blood slide, 150 to 50,
000 parasites/µL
Age 1 year and over, both sexes.
Exclusion criteria: pregnant, mixed infection, danger signs and complications, allergy
to antimalarials, serious illness at time or presentation, antimalarial treatment in last 72
hrs, MQ in last 4 weeks
Setting: Colombia
Interventions 1. AS+MQ
Age 1 to 6: AS 50 mg on days 1, 2, 3 (reported as 0, 1, 2); MQ 250 mg on day 2
Age 7 to 13: AS 100 mg on days 1, 2, 3; MQ 250 mg on days 1, 2, 3
Age > 13: AS 200 mg on days 1, 2, 3; MQ 500 mg on days 1, 2, 3
2. AS+MQ+PQ
As above plus PQ:
Age 1 to 6: 0.3 to 0.6 mg/kg day 3 (reported as day 2).
Age 7 to 13: 22.5 mg/kg day 3.
Age > 13: 45 mg day 3.
Outcomes Assessed on days 2, 3, 4, 8, 15, 22, 29, 36, and 43.
• Clinical recurrence.
• Parasitemia prevalence.
• Parasite density.
• Fever resolution.
• Prevalence of gametocytes.
• Density of gametocytes.
• Adverse effects.
Notes
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Seems to be alternate allocation following
order of arrival (“segun el ordende llegada”)
Allocation concealment (selection bias) Unclear risk Not clear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts noted.
Selective reporting (reporting bias) Low risk No evidence of bias.
Other bias Low risk No suggestion of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Does not seem to be blinded (“con de-
termination no ciega del efecto en grupos
iguales”)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Does not seem to be blinded (“con de-
termination no ciega del efecto en grupos
iguales”)
Wang 2006
Methods Individually RCT
Participants Number of participants: 214 (no dropouts mentioned)
Gabon International Tropical Medicine Institute
Age range: 6 to 60
All had P. falciparum malaria clinical symptoms and blood smear positive.
• Trial group: 108, male 50, female 58, age 16.4 ± 10.5.
• Control group: 106, male 52, female 54, age 18.2 ± 9.4.
Exclusion criteria: N/A
Interventions • Artesunate IM injection, daily for 5 days, 1.2 mg/kg each dose, first dose double.
PQ 3 tablets (base 7.5 mg/tablet, children use half ) once a day, for 5 days.
• Only artesunate IM injection daily for 5 days, 1.2 mg/kg each dose, the first dose
double total 5 days.
Outcomes • Fever clearance time: (hrs) below 37°C continuously measured 4 times.
• Clinical cure rate at day 7.
• Adverse events (not specified).
• Recrudescence rate: symptoms appeared again after clinical cure; parasite
appeared in blood smear by 28 days.
Follow-up: 28 days
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated to be randomized, and the fact that numbers per group
are not equal supports this contention
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
Other bias Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated to be blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated to be blinded.
Abbreviations: AL = artemether-lumefantrine; AQ = amodiaquine; AS = artesunate; CQ = chloroquine; DHAP = dihydroartemisinin-
piperaquine; G6PD = glucose-6-phosphate dehydrogenase; IM = intramuscular; MQ = mefloquine; PCR = polymerase chain
reaction; PQ = primaquine; QN = quinine; RCT = randomized controlled trial; SP = sulfadoxine-pyrimethamine.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baird 2002 Outcome is cure of asexual infection. No gametocyte outcomes
Barber 1929 Not a RCT or quasi-RCT. No controls.
Barber 1932 MDA with PQ; no other drug.
Brueckner 1998 Participants were not infected. Safety only trial.
73Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Bunnag 1980 Comparison of SP plus either five day PQ 15mg, single dose PQ 30mg or single dose PQ 45 mg in patients
with and without gametocytes at presentation. No regimen without PQ. Not a RCT or quasi-RCT. Authors
state they will do further studies, including transmission. No difference in gametocyte outcomes between
regimens, and gametocytes persisted for up to 21 days
Burgess 1961 Comparison of 15 mg, 30 mg and 45 mg dose of PQ. Outcomes were gametocyte prevalence, density,
percent of mosquitoes infected and mean oocysts per mosquito up to eight days. Not a RCT or quasi-RCT.
No other drug. Although this trial used different doses by group (12 participants total), they were assigned
to participants based on age or body size, and therefore it was not a valid comparison of different doses
Cai 1985 Not a RCT.
Carter 2011 No 8AQ in trial.
Che 1987 No mention of randomization. No valid comparison group (pyronaridine phosphate plus sulfadoxine plus
PQ versus pyronaridine phosphate only)
Che 1990 No appropriate control group.
Chevalley 2010 In vitro studies only. Not a RCT.
Clyde 1962 All patients got PQ.
Clyde 1970 Individual before-and-after study, but small number of participants and not controlled
Clyde 1971 Individual before-and-after study, but small number of participants and not controlled
da Silva 1984 Trial of treatment regimens, some including PQ, for P. vivax and P. falciparum.
Degowin 1966 No 8AQ in trial.
Doi 1989 Community observational study. Except for a small pilot study, everyone in the intervention villages got
PQ. There no ‘before’ data from these villages. In the control site, some children received treatment
Giao 2004 No appropriate control group (trial of CV8 (contains PQ) versus atovaquone-proguanil)
Gogtay 1999 Compares QN+PQ against QN+bulaquine. Not a relevant comparison
Gunders 1961 Before-and-after studies of gametocytes and mosquito feeds on people with gametocytes given
pyrimethamine and PQ in doses ranging from 10 mg to 40 mg base. No group without other drug
Hii 1987 Controlled before-and-after study comparing SP+PQ+ITN versus SP+PQ only. Only one cluster per arm
and no group without PQ
Huang 1993 Not a RCT. Unbalanced groups.
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Huang 1996 PQ given to both intervention groups in same regimen. Malaria treatment regimen was varied (low and
higher dose pyronardine/SP)
Huang 2001 No gametocyte outcomes.
Jeffery 1956 Non-randomized comparison of gametocytes and infectivity of artificially infected patients treated with CQ
or CQ+PQ
Jeffery 1963 Observational study of gametocytes and infectivity of two patients given PQ
Jerace 1933 Case series studying gametocytes and infectivity of patients given PQ
Kaneko 1989 Non-randomized community trial comparing SP+PQ in one village with SP only in another. Only one
cluster per arm. The trial was predominantly mass fever test and treat but 75% of people in the intervention
village were treated versus 18% in the control village
Karbwang 1991 Not randomized, no gametocyte outcomes.
Karbwang 1992 Pharmacokinetic study; no gametocyte outcomes or control group
Kyaw 1994 No control group. All patients got PQ.
Li 2007 No gametocyte outcomes.
Li 2010 No gametocyte outcomes.
Lin 2004 All patients got PQ.
Mackerras 1949 No other malaria treatment; one patient fed on before and after PQ
Mapanawang 2016 Pharmacokinetic study of PQ in 12 patients. Not randomized and no gametocyte measures
Rieckmann 1968 Two patients given 45 mg PQ only and fed on by mosquitoes before and after. No other malaria treatment
or control group
Rieckmann 1969 18 patients given CQ alone (N = 2), CQ plus 45 mg PQ (N = 3), or PQ alone in doses ranging from 15
to 45 mg, at either single dose or at one to two week intervals, and fed on before and after one of the doses
of PQ. Non-randomized or quasi-randomized
Santana 2007 Study of 14 day regimen of 15 mg PQ. Some P. falciparum cases were included but study did not distinguish
between the patients with P. falciparum and P. vivax. Study was a comparison of association between
methaemoglobinaemia after 14 day PQ in people with and without G6PD deficiency
Shah 2013 Review of 21 trials from national drug resistance monitoring system of India. Compares 9 sites where
AS+SP+PQ was used with 12 sites where it was not
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Shekalaghe 2010 Randomized comparison of anaemia after SP+AS+PQ versus placebo. Children with haemoglobin < 8 g
were excluded from receiving PQ
Shekalaghe 2011 Trial was a comparison of SP+AS+PQ versus placebo. No comparison of groups with and without PQ
Sun 2011 AS + PQ versus Quinimax only. No appropriate control group.
Suputtamongkol 2003 Comparison of MQ+AS versus MQ + PQ. No appropriate control group
Tangpukdee 2008 Comparison of Artequick (contains PQ) with MQ+AS. No appropriate control group and no gametocyte
outcomes
Yang 1989 All patients got PQ, though different doses of PQ and other malaria treatments
Yeramian 2005 PQ given only to P. vivax patients for 14 days.
Young 1959 No other malaria treatment; case series of PQ given either daily, twice a week or weekly to P. falciparum
patients.
Abbreviations: 8AQ = 8-aminoquinoline; AS = artesunate; CQ = chloroquine; CV8 = combination of dihydroartiemisin, piperaquine,
trimethoprim, and PQ; G6PD = glucose-6-phosphate dehydrogenase; ITN = insecticide treated net; MDA= mass drug administra-
tion; MQ = mefloquine; PQ = primaquine; QN = quinine; RCT = randomized controlled trial; SP = sulfadoxine-pyrimethamine.
Characteristics of studies awaiting assessment [ordered by study ID]
Chen 1993b
Methods
Participants
Interventions
Outcomes
Notes Study not yet located
Ishii 2009
Methods Unclear
Participants Residents of trial villages in Solomon Islands (number not given)
Interventions Testing of clinical malaria patients for G6PD and addition of single dose PQ to other malaria treatment if appropriate
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Outcomes Village prevalence of malaria
Notes Abstract only with no results
Li 2006
Methods
Participants
Interventions
Outcomes
Notes Study not yet located
Abbreviations: G6PD = glucose-6-phosphate dehydrogenase; PQ = primaquine.
Characteristics of ongoing studies [ordered by study ID]
ISRCTN11594437
Trial name or title Assessing the tolerability and safety of single lowdose primaquine inAfrican childrenwith acute uncomplicated
falciparum malaria and glucose 6 phosphate dehydrogenase deficiency in Africa. Primaquine in African
Children (PAC study)
Methods Multi-centre double blind open randomised parallel safety trial (Treatment)
Participants Democratic Republic of Congo and Uganda
Inclusion criteria:
• Aged six months to 11 years old
• Clinically uncomplicated disease
• Fever (= 37.5°C aural) or history of fever within the previous 72 hours
• Positive malaria RDT (Uganda only)
• Positive malaria slide for P. falciparum (mono or mixed infection) of any parasitaemia (Kinshasa only)
• Informed consent provided by patient or relative/legal guardian
Exclusion criteria:
• Malaria danger signs, sign(s) of severe malaria, or decompensated anaemia, including: an inability to
take or retain fluids or oral medications, confusion, prostration, convulsions, respiratory distress, passing of
red or cola-coloured urine (putative “blackwater fever”)
• Severe anaemia (Hb < 6 g/dL)
• Comorbid illness that requires treatment in hospital (physician’s judgement)
• Patients on drugs known to cause haemolysis in G6PDd e.g. dapsone, nalidixic acid
• Known to be allergic to PQ, AL, or DHAPP
• Previous enrolment in the current trial or current enrolment in another trial
77Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
ISRCTN11594437 (Continued)
Interventions Participants are allocated to either the G6PDd group or the G6PD normal group based on their the results
of a G6PD rapid diagnostic test (RDT)
Participants are then randomly allocated as to which dosing group they receive using a computer generated
randomisation list generated for each site. Treatment allocation is placed in a sealed envelope which is opened
once participants receive their study number. The treatment allocation described the Artemisinin based
combination treatment (ACT) to be given and the number of PQ/placebo pack
The four dosing groups are the following:
• Artemether lumefantrine (AL) + single low-dose primaquine (SLDPQ)
• AL + SLDPQ placebo
• Dihydroartemisinin-piperaquine (DHAPP) + single low-dose primaquine (SLDPQ)
• DHAPP + SLDPQ placebo
The dosages for primaquine depends vary with age and the dosing for AL vary with weight (in kg).
DHAPP+SLDPQ dosages are given daily for three days and vary with body weight (in kg). Those who receive
the primaquine/placebo receive it once only at baseline. Follow up continues until day 42
Outcomes Primary outcomes
• Profound anaemia (Hb concentration < 4 g/dL) is measured using the HemoCue machine during the
first days 21 days of follow-up
• Severe anaemia (Hb < 5 g/dL) with clinical features of severe malaria is measured using the HemoCue
machine during the first 21 days of follow-up
Starting date 01/09/2017
Contact information Bob Taylor, Mahidol Oxford Tropical Medicine Clinical Research Unit (MORU) Mahidol University 420/6
Rajvithi Road Rajthevee 10400 Bangkok Thailand
Notes http://isrctn.com/ISRCTN11594437
NCT01906788
Trial name or title The optimal timing of primaquine to prevent malaria transmission after artemisinin-combination therapy
Methods Randomized, open label
Participants 250 male and female participants
Inclusion criteria:
• Age 3 years to 17 years
• Residents of research area
• Willingness to come for complete scheduled follow-up
• Uncomplicated malaria with P. falciparum mono-infection
• Axillary temperature > 37.5°C and < 39.5°C, or history of fever in previous 48 hours
• No history of adverse reactions to trial medication
• Understanding of the trial procedures by parent or guardian and willing to participate by signing
written informed consent forms
Exclusion criteria:
• Haemoglobin below 9 g/dL
• Inability to take drugs orally
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• Known hypersensitivity to any of the drugs given
• Reported treatment with antimalarial chemotherapy in the past two weeks
• Evidence of chronic disease or acute infection other than malaria
• Domicile outside the trial area
• Signs of severe malaria (such as respiratory distress, altered consciousness deep breathing, anaemia)
• Participating in other malaria studies conducted in the region
• Mixed malaria parasite species infection
• Positive pregnant test by urine (UPT) if participant is female aged above 12 years
• G6PD deficient using the fluorescence spot test
Interventions Group 1: AL 6 dose regime orally
Group 2: AL 6 dose regime plus single dose PQ (0.75/kg) on day 0
Group 3: AL 6 dose regimen plus single dose PQ (0.75/kg) on day 2
Outcomes Primary: Gametocyte prevalence and density by microscopy and QT-NASBA on day 14
Secondary:
• Haemoglobin level on days 3, 7, 10 and 14
• Proportion of infected mosquitoes on day 7 after initiation of treatment and the intensity of infection
(oocyst burden) by membrane feeding assay
Starting date May 2013; October 2013 (final data collection date for primary outcome measure)
Contact information Seif Shekalaghe, MD, PhD sshekalaghe@ihi.or.tz +255 755 470472
Notes ClinicalTrials.gov identifier: NCT01906788
Tanzania KCMC and Ifakara
NCT02259426
Trial name or title A double blind randomized controlled trial of dihydroartemisinin-piperaquine alone and in combination
with single dose primaquine to reduce post-treatment malaria transmission
Methods Phase 3 randomized, safety/efficacy study, parallel assignment, double blind (subject, caregiver, investigator,
outcomes assessor)
Participants 120 participants will be recruited in Kenya
Inclusion criteria
• Microscopically detectableP. falciparum gametocyte carriage
• Age 5 years to 15 years
• Gender: both
Exclusion criteria
• Age < 5 years or > 15 years
• Non-falciparum malaria co-infection
• Malaria parasite density = 200,000 parasites/µL
• Clinical symptoms indicating severe malaria
• Axillary temperature = 39°C
• Body Mass Index (BMI) below 16 or above 32 kg/m²
• Haemoglobin concentration below 9.5 g/dL
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• Antimalarials taken in last 2 days
• For women: pregnancy (assessed by clinical examination and urine pregnancy test) or lactation
• Known hypersensitivity to DP or PQ
• History or symptoms, or both indicating chronic illness
• Current use of tuberculosis or anti-retroviral medication
• Unable to give written informed consent
• Unwillingness to participate in two membrane feeding assays
• Travel history to Angola, Cameroon, Chad, Central African Republic, Congo, DR Congo, Equatorial
Guinea, Ethiopia, Gabon, Nigeria and Sudan
• Family history of congenital prolongation of the QTc interval or sudden death or with any other
clinical condition known to prolong the QTc interval such as history of symptomatic cardiac arrhythmias,
with clinically relevant bradycardia or with severe cardiac disease
• Taking drugs that are known to influence cardiac function and to prolong QTc interval, such as class
IA and III: neuroleptics, antidepressant agents, certain antibiotics including some agents of the following
classes - macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating
antihistaminics (terfenadine, astemizole) and cisapride
• Known disturbances of electrolyte balance, for example, hypokalaemia or hypomagnesaemia
• Taking drugs which may be metabolized by cytochrome enzyme CYP2D6 (for example, flecainide,
metoprolol, imipramine, amitriptyline, clomipramine)
• Blood transfusion within last 90 days
Interventions Control: DHAP (Artekin) combination alone
Experimental: DHAP (Artekin) combination alone plus single-dose 0.25 mg/kg PQ
Outcomes Primary outcome
• Gametocyte prevalence on day 7 after initiation of treatment (time frame: day 7 of follow-up)
Secondary outcomes
• Gametocyte carriage during follow-up (time frame: 14 days during follow-up)
• Gametocyte sex-ratio (time frame: 14 days of follow-up)
• Haematological recovery (time frame: 14 days during follow-up)
• Transmission to An. gambiae mosquitoes (time frame: day 3 and 7 during follow-up)
Starting date Registration date 29 September 2014; first enrolment October 2014
Contact information psawa@icipe.org +254 59 22620 (Patrick Sawa MD, ICIPE)
teun.bousema@lshtm.ac.uk +31243617574 (Teun J Bousema, PhD)
Notes ClinicalTrials.gov identifier: NCT02259426
Primary sponsor: London School of Hygiene and Tropical Medicine
NCT02431650
Trial name or title Effectiveness of OZ439 as a gametocytocidal and transmission blocking agent (OZGAM)
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: no masking
Primary purpose: treatment
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Each participant in the cohort will be inoculated on Day 0 with ~2800 viable parasites of P. falciparum-
infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants
is ≥ 5000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood
stage parasitaemia. When gametocytaemia is at the peak (approximately 15 days after administration of
piperaquine), participants will be randomized to receive either OZ439 or a control group (PQ treatment)
Participants 12 adults aged 18 to 55 years
Interventions Experimental: OZ439
Active Comparator: PQ
Outcomes Primary outcome
• Infection success of vector mosquitoes (time frame: from day 10 to 21 post-piperaquine dosing)
assessing the transmissibility by oocyst detection in mosquito midgut preparations following direct and
membrane (indirect) feeding.
Starting date April 2015
Contact information Q-Pharm Clinics Herston, Queensland, Australia, 4006
Prof James McCarthy
QIMR Berghofer Medical Research Institute
Notes
NCT02434952
Trial name or title The tolerability and safety of low dose PQ for transmission blocking in symptomatic falciparum infected
Cambodians
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: open label
Primary purpose: treatment
Participants Cambodia
Inclusion criteria:
• Age ≥ 1 year
• Presentation with a confirmed fever (≥ 38
C axilla or ≥ 37.5°C aural) or history of fever in previous 48 hours ± other clinical features of
uncomplicated malaria
• P. falciparum monoinfection ≥ 1 asexual form / 500 white blood cells
• Informed consent (written/verbal) provided by patient or relative/legal guardian
• Signed assent form for children aged 12 to < 18 years
Exclusion criteria:
• Clinical signs of severe malaria or danger signs
• Pregnant or breast feeding
• Unable or unwilling to take a pregnancy test (for women of child-bearing age)
• Women intending to become pregnant in the next 3 months
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• Allergic to PQ or DHA PP
• Patients taking drugs known to cause acute intravascular haemolytic anaemia (AIHA) in G6PD
deficiency e.g. dapsone, nalidixic acid
• Patients on treatment for a significant illness e.g. HIV, tuberculosis (TB) treatment, steroids
• On drugs that could interfere with anti-malarial pharmacokinetics like antiretrovirals, cimetidine,
ketoconazole, antiepileptic drugs, rifampicin
Interventions Experimental: DHA PP plus PQ, G6PD deficiency
Active comparator: DHA PP plus PQ, G6PD normal
Active comparator: DHA PP alone, G6PD deficiency
Active comparator: DHA PP alone, G6PD normal
Outcomes Primary outcomes:
• Haemoglobin concentration [Time Frame: Day 7] Compare haemoglobin concentrations in g/dL
between the G6PD deficient arm given DHA PP plus PQ, and the G6PD normal arm receiving the same
regimen
Starting date October 2014
Contact information Dysoley Lek, MD, National Centre for Parasitology, Entomology and Malaria Control, Cambodia
Notes https://clinicaltrials.gov/ct2/show/NCT02434952
NCT02831023
Trial name or title Phase 2 efficacy study of primaquine and methylene blue: efficacy, safety, and pharmacokinetics of sulphadox-
ine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ plus primaquine, dihydroartemisinin-piperaquine (DP),
DP plus methylene blue for preventing transmission of P. falciparum gametocytes in Mali
Methods Interventional
Allocation: randomized; endpoint classification: safety/efficacy study; interventionmodel: parallel assignment;
masking: single blind (outcomes assessor), primary purpose: treatment
Phase 2
Participants Mali
Inclusion criteria:
• Glucose-6-phosphate dehydrogenase (G6PD) normal defined by CareStart™ G6PD rapid diagnostic
test (RDT) or the OSMMR2000 G6PD semi-qualitative test
• Absence of symptomatic falciparum malaria, defined by fever upon enrolment
• Presence of P. falciparum gametocytes on thick blood film at a density > 30 gametocytes/µL (i.e. = 2
gametocytes recorded in the thick film against 500 white blood cells)
• No allergies to study drugs
• No self-reported use of antimalarial drugs over the past 7 days (as reported by the participant)
• Haemoglobin = 10 g/dL
• Individuals weighing < 80 kg
• No evidence of severe or chronic disease
• Written, informed consent
Exclusion criteria:
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• Age < 5 years or > 50 years
• Female gender
• Blood thick film negative for sexual stages of malaria
• Previous reaction to study drugs/known allergy to study drugs
• Signs of severe malaria, including hyperparasitaemia, defined as asexual parasitemia >100,000
parasites/µL)
• Signs of acute or chronic illness, including hepatitis
• Use of other medications (with the exception of paracetamol and/or aspirin) - Consent not given
Age minimum: 5 Years
Age maximum: 50 Years
Gender: Male
Interventions Drug: 0.25 mg/kg PQ
Drug: Amodiaquine
Drug: Dihydroartemisinin-piperaquine
Drug: Methylene blue
Drug: Sulphadoxine-pyrimethamine
Outcomes Primary:
Mosquito infectivity assessed through membrane feeding assays (time frame: 7 day)
Starting date July 2016
Contact information Alassane Dicko, MD adicko@icermali.org; Ingrid Chen, PhD ingrid.chen@ucsf.edu
Notes https://clinicaltrials.gov/show/NCT02831023
NCT02851108
Trial name or title Methylene blue against falciparum malaria in Burkina Faso BlueACTn
Safety of artesunate-amodiaquine combined with methylene blue or PQ for falciparum malaria treatment in
African children: a randomised controlled trial
Methods Interventional
Allocation: randomized; endpoint classification: safety/efficacy study; interventionmodel: parallel assignment;
masking: open label; primary purpose: treatment
Phase 2
Participants Burkina Faso
Inclusion criteria:
• Weight = 6 kg
• Uncomplicated malaria caused by P. falciparum
• Asexual parasites = 2 000/µL and = 100,000/µL
• Axillary temperature = 37.5°C or a history of fever during the last 24 hours
• Burkinabe nationality
• Permanent residence in the study area with no intention of leaving during the surveillance period
• Written informed consent of parents or care takers
Exclusion criteria:
• Severe malaria
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• Mixed malaria infection
• Vomiting (> 2 times within 24 hours before the visit)
• Any apparent significant disease, including severe malnutrition
• A history of a previous, significant adverse reaction or known allergy to one or more of the study drugs
• Anaemia (haemoglobin < 7 g/dL)
• Treated in the same trial before
• All modern antimalarial treatment prior to inclusion (last 7 days)
• Therapy with serotonin reuptake inhibitors (e.g. citalopram, escitalopram, fluoxetine, Paroxetine,
Sertraline)
• Simultaneous participation in another investigational study
• Patients with known HIV/AIDS disease
• Therapy with drugs known to inhibit the liver enzymes cytochrome 2A6 (e.g. methoxsalen,
pilocarpine, tranylcypromine) and/or cytochrome 2C8 (e.g. trimethoprim,
• ketoconazole, ritonavir, saquinavir, lopinavir, gemfibrozil, montelukast)
Age minimum: 6 months
Age maximum: 59 months
Gender: Both
Interventions Drug: methylene blue
Drug: PQ
Outcomes Primary: Change in haemoglobin compared to the baseline (time frame: 7 days)
Starting date October 2016
Contact information Olaf Müller, Prof. Dr. olaf.mueller@urz.uni-heidelberg.de
Notes https://clinicaltrials.gov/show/NCT02851108
PACTR201611001859416
Trial name or title Addition of low dose primaquine to artemether-lumefantrine for the treatment of uncomplicated malaria
Methods RCT
Parallel: different groups receive different interventions at same time during study,
Randomized
Random number generation, stratified by clinic, prepared by an independent statistician using a valid system,
Sealed opaque envelopes,
Participants South Africa
Inclusion criteria:
• P. falciparum positive by RDT
• Age b 2 years
• Weight over 10 kg
• Prescribed artemether-lumefantrine according to standard practice
• Informed consent (by legally acceptable representative if under 18 years of age)
• Assent in children aged 7 and above
• Intention to remain in the study area for the duration of the follow-up period
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Exclusion criteria:
• Evidence of severe illness/danger signs
• Known allergy to study medications
• Medical history of haemolysis, rheumatoid arthritis, lupus erythematosus or cardiac disease
• In patients receiving concurrently other drugs that are cause haemolysis, bone marrow suppression, or
QTc interval prolongation
• Hb 7 g/dL
• A decrease in Hb of b 2 g/dL between day 0 and day 3 prior to PQ dose
• Currently menstruating
• Pregnant or breastfeeding
• History of any antimalarials (including PQ) taken within the last 4 weeks
• Blood transfusion within the last 90 days
Age minimum: 2 years
Age maximum: 100 years
Gender: both
Interventions PQ plus standard of care (AL)
Standard of care (AL)
Outcomes Primary:
Change in mean haemoglobin (Hb) as measured by HemoCue on day 3
Changes in gametocyte prevalence on days 7 and 14 using RT-PCR
Starting date 2016-11-18
Contact information Jaishee Raman, jaishreer@nucd.ac.za ; Karen Barnes karen.barnes@uct.ac.za
Notes www.pactr.org/ATMWeb/appmanager/atm/atmregistry?dar=true&tNo=PACTR201611001859416
Abbreviations: AL = artemether-lumefantrine; BSPC = blood stage Plasmodium falciparum challenge; DHA = dihydroartemisinin;
DHAP = dihydroartemisinin-piperaquine; DHAPP = Dihydroartemisinin-piperaquine; DP = dihydroartemisinin-piperaquine;
G6PD = glucose-6-phosphate dehydrogenase; Hb = haemoglobin; PCR = polymerase chain reaction; PP = piperaquine phosphate;
PQ = primaquine; QT-NASBA = real-time quantitative nucleic acid sequence-based amplification; RT-PCR = real time PCR;
SLDPQ = single low-dose primaquine; SP-AQ = sulphadoxine-pyrimethamine-amodiaquine.
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D A T A A N D A N A L Y S E S
Comparison 1. Artemisinin treatment regimen: PQ versus no PQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants infectious, day 3 or
4, by dose
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 0.2 to 0.25 mg/kg 3 105 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.88]
1.2 0.4 to 0.5 mg/kg 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.02, 0.94]
1.3 0.75 mg/kg 1 101 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.68]
2 Participants with gametocytes
(PCR), day 3 or 4, by dose
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 0.2 to 0.25 mg/kg 3 414 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.87, 1.21]
2.2 0.4 to 0.5 mg/kg 3 418 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.93, 1.28]
2.3 0.75 mg/kg 2 394 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.75, 1.13]
3 Participants with gametocytes
(microscopy), day 3 or 4, by
dose
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 0.2 to 0.25 mg/kg 3 490 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.21, 2.50]
3.2 0.4 to 0.5 mg/kg 2 225 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.33, 2.25]
3.3 0.75 mg/kg 3 248 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.20, 0.85]
4 Participants infectious, day 8, by
dose
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 0.2 to 0.25 mg/kg 4 243 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.07, 1.58]
4.2 0.4 to 0.5 mg/kg 4 246 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.57]
4.3 0.75 mg/kg 2 181 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.02, 1.41]
5 Participants with gametocytes
(PCR), day 8, by dose
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 0.2 to 0.25 mg/kg PQ 4 532 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.41, 0.65]
5.2 0.4 to 0.5 mg/kg PQ 5 758 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.29, 0.48]
5.3 0.75 mg/kg PQ 5 793 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.23, 0.43]
6 Participants with gametocytes
(microscopy), day 8, by dose
9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 0.2 to 0.25 mg/kg 3 491 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.16, 0.78]
6.2 0.4 to 0.5 mg/kg 2 225 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.08, 0.75]
6.3 0.75 mg/kg 6 1443 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.19, 0.37]
7 Gametocyte clearance time
(PCR), by dose
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 0.2 to 0.25 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 0.4 to 0.5 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Area under curve of gametocytes
(PCR), days 1 to 15, by dose
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 0.2 to 0.25 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 0.4 to 0.5 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Participants with severe
haemolysis, by dose
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 0.2 to 0.25 mg/kg 4 752 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.69, 1.39]
9.2 0.4 to 0.5 mg/kg 2 260 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [0.38, 6.30]
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9.3 0.75 mg/kg 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Mean max change in
haemoglobin concentration, by
dose
4 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 0.2 to 0.25 mg/kg 2 435 Mean Difference (IV, Random, 95% CI) 0.13 [-0.07, 0.33]
10.2 0.4 to 0.5 mg/kg 2 475 Mean Difference (IV, Random, 95% CI) 0.18 [-0.08, 0.44]
10.3 0.75 mg/kg 3 538 Mean Difference (IV, Random, 95% CI) 0.05 [-0.04, 0.14]
11 Percent change in haemoglobin,
day 8, by dose
4 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 0.2 to 0.25 mg/kg 2 492 Mean Difference (IV, Random, 95% CI) 0.25 [-0.99, 1.50]
11.2 0.4 to 0.5 mg/kg 1 230 Mean Difference (IV, Random, 95% CI) 0.43 [-3.40, 4.26]
11.3 0.75 mg/kg 2 334 Mean Difference (IV, Random, 95% CI) 1.46 [-1.70, 4.63]
12 Max percent change in
haemoglobin, by dose
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 0.2 to 0.25 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 0.4 to 0.5 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 0.75 mg/kg 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Haemoglobinuria/dark urine 3 527 Odds Ratio (M-H, Fixed, 95% CI) 3.40 [2.15, 5.38]
14 Other adverse effects (CNS
symptoms)
6 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Headache 5 1706 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.66, 1.36]
14.2 Paresthesia 1 331 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.13, 6.80]
14.3 Dizziness 4 1335 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.74, 1.23]
14.4 Meningitis 1 441 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 2.13]
14.5 Blurred vision 1 217 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.12]
14.6 Insomnia 1 808 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.64, 1.47]
15 Other adverse effects (systemic) 6 4142 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.74, 1.24]
15.1 Fatigue 2 236 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.46, 2.19]
15.2 Pruritis 1 347 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 Fever 4 1056 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.65, 1.55]
15.4 Muscle ache/pain 2 398 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.12, 3.55]
15.5 Skin rash 3 921 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [0.46, 5.01]
15.6 Pallor 2 704 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.59, 1.54]
15.7 Weakness/asthenia 2 480 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.43, 1.49]
16 Other adverse effects
(respiratory symptoms)
5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Cough 2 488 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.77, 2.54]
16.2 Runny nose 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.07, 3.61]
16.3 URTI/respiratory
infection
2 488 Odds Ratio (M-H, Fixed, 95% CI) 2.57 [0.68, 9.72]
16.4 Bronchitis 1 351 Odds Ratio (M-H, Fixed, 95% CI) 2.34 [0.50, 10.87]
16.5 Rhinitis/rhinobronchitis 2 398 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.10, 5.83]
16.6 Shortness of breath 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 4.45]
16.7 Otitis 1 351 Odds Ratio (M-H, Fixed, 95% CI) 2.36 [0.11, 50.02]
16.8 Epistaxis 1 351 Odds Ratio (M-H, Fixed, 95% CI) 1.41 [0.06, 35.04]
16.9 Pneumonia 1 441 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 2.24]
16.10 Cold sores 1 217 Odds Ratio (M-H, Fixed, 95% CI) 1.33 [0.29, 6.10]
16.11 Cyanosis 1 263 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Other adverse effects
(gastrointestinal symptoms)
7 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Nausea 5 1624 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.88, 1.64]
17.2 Vomiting 7 2459 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.65, 1.56]
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17.3 Abdominal pain 7 2453 Odds Ratio (M-H, Fixed, 95% CI) 1.14 [0.86, 1.51]
17.4 Diarrhoea/dysentery/
stooling
7 2462 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.50, 1.10]
17.5 Anorexia/loss of appetite 3 1296 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.45, 0.95]
18 Other adverse effects
(Miscellaneous)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 Back pain 1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.04, 2.05]
18.2 Burning with urination 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.06, 29.31]
18.3 Pain with urination 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.06, 29.31]
18.4 Whitlow 1 47 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.06, 29.31]
18.5 Leg osteoarthritis 1 47 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.14]
18.6 Uncomplicated malaria 1 351 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.12, 4.04]
18.7 Dental pain 1 351 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 3.67]
18.8 High transaminase 1 351 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 3.67]
18.9 Palpebral inflammation 1 351 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 3.67]
18.10 Wound/trauma 2 792 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.12, 0.97]
18.11 Foot trauma 1 351 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.06, 33.01]
18.12 Foot inflammation 1 351 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.06, 33.83]
18.13 Skin infection 1 441 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.30, 2.29]
18.14 Palpitations 1 808 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.80, 1.37]
18.15 Unspecified 2 655 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.46, 1.96]
Comparison 2. Artemisinin treatment regimen: PQ 0.25 versus 0.50 mg/kg
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants infectious, day 3 to
4
3 116 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.06, 13.54]
2 Participants with gametocytes
(PCR), day 3 to 4
3 424 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.80, 1.09]
3 Participants with gametocytes
(microscopy), day 3 to 4
2 231 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.68, 2.20]
4 Participants infectious, day 8 4 237 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.14, 6.48]
5 Participants with gametocytes
(PCR), day 8
4 559 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.97, 1.82]
6 Participants with gametocytes
(microscopy), day 8
2 235 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.51, 6.38]
88Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Comparison 3. Non-artemisinin treatment regimen: PQ versus no PQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants infectious, day 5, by
dose
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 0.75 mg/kg 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.62]
2 Participants with gametocytes
(microscopy), day 4 to 5, by
dose
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 0.4 to 0.5 mg/kg 1 221 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.62, 1.13]
2.2 0.75 mg/kg 2 52 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.48, 1.50]
3 Participants infectious, day 8, by
dose
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 0.75 mg/kg PQ 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.01, 0.45]
4 Participants with gametocytes
(microscopy), day 8, by dose
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 0.4 to 0.5 mg/kg PQ 1 216 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.49, 0.75]
4.2 0.75 mg/kg PQ 4 186 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.25, 0.62]
5 Gametocyte clearance time 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Any adverse effect 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. PQ versus other 8AQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with gametocytes
(microscopy), day 8
2 112 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.26, 0.66]
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
Com-
parator
Trial Arm Place G6PD
status
Parasite
species
Part-
ner or al-
ternative
drug
Propor-
tion with
game-
tocytes at
onset
(control
group)
Propor-
tion with
game-
tocytes at
onset (ex-
perimen-
tal group)
Day(s)*
PQ given
Target
PQ dose
per day
Artemisinin-based partner
AS or
ACT
Arango
2012
b Colombia Not
reported
Pf only AS+MQ
days 1 to 3
34.8%
Mic
(N = 23)
26.3%
Mic
(N = 19)
day 2 0.75 mg/
kg
Dicko
2016
a Mali Only non-
deficient
includ 1
Pf only DHAP
days 1 to 3
100%
Mic
(N = 15)
Table 1
100%
Mic (N =
16)
day 1 0.0625
mg/kg**
b 100%
Mic (N =
16)
day 1 0.125 mg/
kg**
c 100%
Mic (N =
15)
day 1 0.25 mg/
kg
d 100%
Mic (N =
17)
day 1 0.5 mg/kg
El-Sayed
2007
Sudan
(east)
Not
reported
Pf only AS+SP
days 1 to 3
11.5%
PCR
(N = 52)
Table 2
11.5%
PCR
(N = 52)
day 4 0.75 mg/
kg
Eziefula
2013
a Uganda Only non-
deficient
included2
(PCR test-
ing of
those in-
cluded af-
ter FST)
Pf only AL
days 1 to 3
23.1%
Mic
(N = 117)
79.8%
PCR
(N = 114)
Table 1
24.3%
MIc
(N = 115)
86.7%
PCR
(N = 113)
day 3 0.1 mg/
kg**
b 20.4%
Mic
(N = 113)
78.7%
PCR
(N = 108)
day 3 0.4 mg/kg
c 22.4%
Mic
(N = 116)
82.0%
day 3 0.75 mg/
kg
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
(Continued)
PCR
(N = 111)
Gonçalves
2016a
a Burkina
Faso
Only non-
deficient
included3
Pf only AL
days 1 to 3
17.7%
Mic
(N = 62)
Table 2
32% Mic
(N = 75)
92.9%
PCR (N =
70)
day 3 0.25 mg/
kg
b 20.5%
Mic
(N = 73)
85.5%
PCR (N =
62)
day 3 0.4 mg/kg
Gonçalves
2016b
a Burkina
Faso
Only non-
deficient
included3
Pf only AL
days 1 to 3
69.4%
Mic
(N = 49)
Table 2
55.3%
Mic (N =
47)
93.7%
PCR (N =
48)
day 3 0.25 mg/
kg
b 83.3%
Mic (N =
46)
100.0%
PCR (N =
46)
day 3 0.4 mg/kg
Lin 2017 Cambo-
dia
Screened
and
severely
deficient
excluded4
Pf or
Pf+Pv
DHAP
days 1 to 3
10% Mic
44% PCR
(N = 51)
Table 1
8% Mic
49% PCR
(N = 50)
Table 1
day 3 0.75 mg/
kg
Mwaiswelo
2016
Tanzania Screened
and all in-
cluded5
Pf only AL
days 1 to 3
1 patient
had game-
tocytes
at recruit-
ment but
treatment
group not
given
0.5% Mic
(N = 220)
both
groups
day 1 0.25 mg/
kg
Okebe
2016
a The Gam-
bia
Only non-
deficient
included2
Pf only DHAP
days 1 to 3
47.7%
PCR
(N = 153)
Table 1
53.4%
PCR (N =
148)
day 3 0.2 mg/kg
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
(Continued)
b 54.6%
PCR
(N = 152)
day 3 0.4 mg/kg
c 53.4%
PCR
(N = 146)
day 3 0.75 mg/
kg
Pukrit-
tayakamee
2004
c Thailand Only non-
de-
ficient in-
cluded10
Pf only AS
days 1 to 7
26.1%
Mic
(N = 23)
Table 3
26.0%
Mic
(N = 50)
days 1 to 7 0.5 mg/kg
Shekalaghe
2007
Tanzania
(North
east)
Screened
and all in-
cluded6
Pf only AS+SP
days 1 to 3
26.4%
Mic (N =
63)
88.2%
PCR
(N = 51)
Table 1
18.9%
Mic
(N = 53)
90.6%
PCR
(N = 53)
day 3 0.75 mg/
kg
Smithuis
2010
a Myanmar
(3 states)
Not
screened
Pf or
mixed
AS+AQ
days 1 to 3
32.1%
Mic
(N = 84)
36.6%
Mic
(N = 71)
day 1 0.75 mg/
kg
b AL
days 1 to 3
34.5%
Mic
(N = 84)
32.1%
Mic
(N = 78)
day 1 0.75 mg/
kg
c AS+MQ
fixed dose
days 1 to 3
31.3%
Mic
(N = 83)
27.9%%
Mic
(N = 86)
day 1 0.75 mg/
kg
d AS
days 1 to 3
+ MQ day
1 loose
30.5%
Mic
(N = 82)
26.6%
Mic
(N = 79)
day 1 0.75 mg/
kg
e DHAP
days 1 to 3
43.6%
Mic
(N = 78)
32.5%
Mic
(N = 83)
day 1 0.75 mg/
kg
Sutanto
2013
Indonesia
(south
Sumatra)
Only non-
deficient
included7
Pf only DHAP
days 1 to 3
17.4%
Mic
(N = 178)
Figure 1
24.0%
Mic
(on day 3)
(N = 171)
day 4 0.75 mg/
kg
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
(Continued)
Tine
2017
a Senegal Screened
and all in-
cluded5
Pf only AL
days 1 to 3
6.7% Mic
(N = 135)
Table 5
7.9% Mic
(N = 139)
Table 5
day 1 0.25 mg/
kg
b DHAP
days 1 to 3
c AS+AQ
days 1 to 3
Vásquez
2009
Colombia
(Antio-
quia)
Not
reported
Pf only AS+MQ
days 1 to 3
(MQ only
on day
2 for chil-
dren < 6)
16% Mic
(N = 25)
Figure 1
estimated
24.0%
Mic
(N = 25)
day 3 45 mg
(~0.75
mg/kg)
Wang
2006
Gabon Not
reported
Pf AS i.m.
days 1 to 5
Not
reported
(N = 106)
Not
reported
(N = 108)
days 1 to 5 22.5 mg
(~0.38
mg/kg)
Non-artemisinin partner
CQ or
(CQ+SP)
Kamtekar
2004
a India
(Mumbai)
Not
screened
Pf only CQ
days 1 to 3
or
CQ
days 1 to 3
+ SP day 1
100%
Mic
(N = 44)
100%
Mic
(within 3
days)
(N = 45)
day 4 45 mg
(~0.75
mg/kg)
Khoo
1981
Malaysia
(Sabah)
Only de-
ficient in-
cluded8
Pf, Pv or
mixed
CQ
days 1 to 3
Not
reported
Not
reported
days 1 to 3 25 mg
(~0.42
mg/kg)
Kolaczin-
ski
2012
a Pakistan
(3 Afghan
refugee
camps)
Not
reported
Pf only CQ days 1
to 3
17.6%
Mic
(N = 239)
Table 2
(com-
bined
CQ,
CQ+AS,
SP, SP+AS
groups)
19.7%
Mic
(N = 76)
day 3 0.5
mg/kg
Leder-
man
2006
a Indone-
sia (Cen-
tral Java)
Only non-
deficient
included9
Pf only CQ
days 1 to 3
+ SP day 1
8.2% Mic
(N = 61)
Figure 3
est (com-
bined
CQ,
25% Mic
(N = 28)
Figure 3
est
day 1 45 mg
(~0.75
mg/kg)
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
(Continued)
CQ+SP
groups)
b 14.3%
(N = 28)
Figure 3
est
day 3 45 mg
(~0.75
mg/kg)
SP Kolaczin-
ski
2012
b Pakistan
(2 Afghan
refugee
camps)
Not
reported
Pf only SP day 1 See above
under Ko-
laczinski
2012 a
27.1%
Mic
(N = 85)
day 1 0.5 mg/kg
AQ+SP Arango
2012
a Colombia Not
reported
Pf only AQ
days 1 to 3
+ SP day 1
15% Mic
(N = 20)
Table 3
30% Mic
(N = 20)
day 2 0.75 mg/
kg
MQ or
(MQ+SP)
Chen
1993a
China Not
reported
Pf only MQ day 1 100%
Mic
(N = 6)
100%
Mic
(N = 6)
day 1 45
mg (~0.75
mg/kg)
Chen
1994
China
(Hainan
province)
Not
reported
Pf only MQ
day 1
100%
Mic
(N = 9)
MQ
group
only
100%
Mic
(N = 9)
day 1 45 mg
(~0.75
mg/kg)
Singhasi-
vanon
1994
Thailand
(Bangkok)
Not
reported
Pf only MQ+SP
fixed day 1
Not
reported
(N = 11)
Not
reported
(N = 7)
day 1 0.75 mg/
kg
QN Kamtekar
2004
b India
(Mumbai)
Not
screened
Pf only QN i.v.
days 1 to 2
and orally
days 1 to 7
88.6%
Mic
(N = 44)
100%
Mic
(within 3
days)
(N = 45)
day 8 45 mg
(~0.75
mg/kg)
Pukrit-
tayakamee
2004
a Thailand Only non-
de-
ficient in-
cluded10
Pf only QN
days 1 to 7
23.3%
Mic
(N = 60)
QN,
QN+TC
groups
18.6%
Mic
(N = 59)
days 1 to 7 0.25 mg
base/kg
b 22.4%
Mic
(N = 67)
days 1 to 7 0.5 mg
base/kg
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Table 1. Trial locations, partner drugs, gametocyte status at onset, G6PD status, and PQ dose and treatment schedule
(Continued)
PQversus
Bu-
laquine
Gogtay
2004
India
(Mumbai)
Only non-
de-
ficient in-
cluded10
Pf QN
+ doxycy-
cline days
1 to 7
+ BQ day
4
No con-
trol group
without 8-
AQ
100%
Mic
(N = 22)
day 4 45 mg
(~0.75
mg/kg)
Gogtay
2006
India Only non-
deficient
included
10
Pf QN
+ doxycy-
cline days
1 to 7
+ BQ day
4
No con-
trol group
without 8-
AQ
100%
Mic
(N = 93)
day 4 45 mg
(~0.75
mg/kg)
*first day of any treatment = day 1
**arm excluded as dose < 0.2 mg/kg
1G6PD colorimetric method, R&D diagnostics, Papagos, Greece.
2G6PD by fluorescence spot test.
3G6PD by Binax Now Alere rapid test.
4G6PD by fluorescent spot test (R&D diagnostics, Greece) and quantitative enzyme activity testing (Trinity Biotech, Ireland).
5G6PD (phenotypic) by CareStart ™ Access Bio test; (genotypic) by PCR and RFLP digestion for the two most common Afrcian
G6PD polymorphisms.
6G6PD by detection of single nucleotide polymorphisms (G202A, A376G) by PCR and ELISA.
7G6PD by qualitative test.
8G6PD by Brewer’s methaemoglobin reduction test.
9G6PD by semi-quantitative G6PD assay.
10G6PD method not reported.
Abbreviations: G6PD = glucose-6-phosphate dehydrogenase; FST = fluorescent spot test; PQ = primaquine; CQ = chloroquine; SP =
sulfadoxine-pyrimethamine; MQ =mefloquine; QN = quinine; AS = artesunate; ACT = artemisinin-based combination therapy; 8AQ:
8-aminoquinoline; AQ = amodiaquine; AL = artemether-lumefantrine; DHAP = dihydroxyartemisinin-piperaquine; BQ = bulaquine;
i.v. = intravenous injection; i.m. = intramuscular injection; Mic = microscopy; Pf = P. falciparum; Pv = P. vivax.
Table 2. Infectivity to mosquitoes baseline
Dose Study With PQ Without PQ Absolute
difference
(reduc-
tion or
increase)
in % of
mosquitoes
infected
in PQ
group
Average
number of
mosquitoes
dissected
per par-
ticipant
(both
arms com-
bined)
Total
number
Num-
ber of in-
Average
% of
Total
number of
Num-
ber of in-
Average %
of
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Table 2. Infectivity to mosquitoes baseline (Continued)
of partici-
pants
fectious
people
mosquitoes
infected
partici-
pants
fectious
people
mosquitoes
infected
0.25 mg/
kg
Dicko
2016
15 14 35.5 14 10 6.7 +28.8 143.1
Gonçalves
2016b
27 8 4.5 32 15 14.8 −10.3 44.0
0.4 to 0.5
mg/kg
Dicko
2016
14 12 11.0 14 10 6.7 +4.3 136.6
Gonçalves
2016b
20 7 8.9 32 15 14.8 −5.8 44.3
0.75 mg/
kg
Lin 2017 50 1 1.4 51 6 5.3 −3.9 50
Abbreviations: PQ: primaquine.
Table 3. Infectivity to mosquitoes day 3-4
Dose Study With PQ Without PQ Absolute
difference
(reduc-
tion or
increase)
in % of
mosquitoes
infected
in PQ
group
Average
number of
mosquitoes
dissected
per partic-
ipant
(both
arms com-
bined)
Total
number
of partici-
pants
Num-
ber of in-
fectious
people
Average %
of
mosquitoes
infected
Total
number of
partici-
pants
Num-
ber of in-
fectious
people
Average %
of
mosquitoes
infected
0.25 mg/
kg
Dicko
2016
15 1 0.6 13 7 8.1 −7.5 71.6
Gonçalves
2016a
27 0 0.0 32 0 0.0 0.0 26.9
Gonçalves
2016b
23 0 0.0 19 0 0.0 0.0 45.6
0.4 to 0.5
mg/kg
Dicko
2016
14 1 0.3 13 7 8.1 −7.8 70.2
Gonçalves
2016a
20 0 0.0 32 0 0.0 0.0 33.4
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Table 3. Infectivity to mosquitoes day 3-4 (Continued)
Gonçalves
2016b
28 0 0.0 19 0 0.0 0.0 45.6
0.75 mg/
kg
Lin 2017 50 1 1.4 51 5 6.6 -5.2 50
Abbreviations: PQ: primaquine.
Table 4. Infectivity to mosquitoes day 8
Dose Study With PQ Without PQ Absolute
difference
(reduc-
tion or
increase)
in % of
mosquitoes
infected
in PQ
group
Average
number of
mosquitoes
dissected
per par-
ticipant
(both
arms com-
bined)
Total
number of
partici-
pants
Num-
ber of in-
fectious
people
Average %
of
mosquitoes
infected
Total
number of
partici-
pants
Number
of infec-
tious peo-
ple
Average %
of
mosquitoes
infected
0.2 to 0.25
mg/kg
Dicko
2016
15 0 0.0 13 3 3.7 −3.7 72.8
Gonçalves
2016a
27 0 0.0 32 0 0.0 0.0 26.6
Gonçalves
2016b
49 0 0.0 49 1 0.2 −0.2 43.7
Okebe
2016¹
44 1 29.2 46 1 1.3 +27.9 80
0.4 to 0.5
mg/kg
Dicko
2016
14 1 0.1 13 3 3.7 −3.6 71
Gonçalves
2016a
20 0 0.0 32 0 0.0 0.0 31.4
Gonçalves
2016b
46 0 0.0 49 1 0.2 −0.2 43.4
Okebe
2016
42 0 0.0 46 1 1.3 −1.3 80
0.75 mg/
kg
Lin 2017 48 0 0.0 48 4 6.9 −6.9 50
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Table 4. Infectivity to mosquitoes day 8 (Continued)
Okebe
2016¹
39 0 0.0 46 1 1.3 −1.3 80
¹Okebe 2016 reported the median number of mosquitoes per person.
Abbreviations: PQ: primaquine.
WH A T ’ S N E W
Last assessed as up-to-date: 21 July 2017.
Date Event Description
9 February 2018 Amended PLS title corrected to ’A single dose of primaquine added to malaria treatment to prevent malaria
transmission’
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 9, 2012
Date Event Description
1 February 2018 New search has been performed Search updated to 21 July 2017. We included seven new
trials (Dicko 2016;Gonçalves 2016a;Gonçalves 2016b;
Mwaiswelo 2016; Okebe 2016; Lin 2017; Tine 2017)
and four additional publications from a previously in-
cluded trial (Eziefula 2013).The new trials included di-
rect measures of infectiousness of people to mosquitoes
and these data were included
1 February 2018 New citation required and conclusions have changed This is an update of a review last updated in 2015.
4 February 2015 New citation required but conclusions have not changed New citation.
4 February 2015 New search has been performed Search updated to 5 January 2015. No new trials were
included. We simplified the text. We corrected data ex-
traction errors in one study and corrected the results and
’Summary of findings’ table. We adjusted the wording
around “evidence of no effect”. We took into account
comments and criticisms received. These criticismswere
also published in theMalaria Journal in 2014, so this re-
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(Continued)
vision corrects the minor data extraction errors pointed
out in this article. The conclusions are not changed
24 June 2014 New citation required and conclusions have changed We stratified the analysis by dose of primaquine and
added new studies.We clarified the excluded studies and
adjusted the conclusions
24 June 2014 New search has been performed New studies added.
C O N T R I B U T I O N S O F A U T H O R S
2018 update
PMG and HG screened the abstracts, added the new studies, and extracted the data. LC and PG revised the GRADE analysis and
‘Summary of findings’ tables. All authors contributed to interpretation of results and rewriting the review.
Graves 2015: PMG, HG, and PG contributed to adjusting the data and updating the text.
Graves 2014: PMG and HG added the new studies. PG helped rewrite the review. All review authors contributed to the interpretation
of the results and the conclusions drawn.
Graves 2012: two review authors (PMG andHG) independently screened all abstracts, applied inclusion criteria and extracted data. PG
helped structure the review and contributed to the logic framework of the ‘Summary of findings’ tables. All review authors contributed
to the writing of the review, the interpretation of the results, and the conclusions drawn.
D E C L A R A T I O N S O F I N T E R E S T
We have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the
review (for example, employment, consultancy, stock ownership, honoraria, or expert testimony).
This review and the salary of PG is supported by a DFID grant aimed at ensuring the best possible systematic reviews, particularly
Cochrane Reviews, are completed on topics relevant to the poor in low- and middle-income countries. DFID does not participate in
the selection of topics, in the conduct of the review or in the interpretation of findings. PG is a member of the WHO Guidelines for
the Treatment of Malaria Group that made the recommendation for PQ to reduce P. falciparum malaria transmission.
PMG was a member from 2012 to 2016 of the WHO Malaria Policy Advisory Committee, which provides independent strategic
advice in forming WHO policies in malaria.
HG and LC have no known conflicts of interest.
None of the review authors are investigators on any of the included trials.
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S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Grant: 5242
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2012 version
1. After reading the trials, we added several new outcomes and modified some outcomes; we deleted two outcomes.
Changes to primary outcomes:
• Proportion of participants with gametocytes: we added: by microscopy and PCR;
• We added: Proportion of participants infectious;
• We included: Gametocyte density (by microscopy and PCR);
• We added: Gametocyte clearance time and duration of gametocyte carriage.
We arranged the primary outcomes to capture the three categories: transmission intensity, infectiousness and potential infectiousness.
Changes to secondary outcomes:
• We deleted AUC of asexual parasite density over time. We did not identify any relevant data;
• We added asexual clearance time.
Changes to adverse events:
• We deleted: all adverse events (data reported was minimal and not in a form that was easily summarized. The main question is
whether there are serious adverse events);
• We modified haemolysis or drop in haemoglobin or PCV (as assessed/defined in each trial) by deleting reference to G6PD since
these outcomes occur in non-G6PD people too. We also added PCV since this was used in some trials as a measure of anaemia.
2. In the first version of the review, we deleted the objective: “To compare the effects of different doses and schedules of PQ given to
reduce infectiousness” and we modified the definition of control in comparisons accordingly. We only included controls without PQ.
We deleted the comparison of different doses of PQ with identical other treatment regimens since it does not answer the important
question of whether adding PQ is effective.We included one trial with two arms using different doses of PQ with same other treatment
regimens as two separate arms within the same comparison.
2014 version
In the June 2014 update, we reversed this decision. We planned to use the following comparisons described in the protocol:
• CQ (with and without PQ, or with different doses of PQ);
• SP (with and without PQ, or with different doses of PQ);
• CQ plus sulphadoxine + pyrimethamine (with and without PQ, or with different doses of PQ);
• Artemisinin derivatives (with and without PQ, or with different doses of PQ);
• Other drugs (with and without PQ, or with different doses of PQ).
In the review, we changed the groups, added some, and combined some for the following reasons:
a. some trials combined two types of malaria treatment regimens, not distinguishing the patients who received each one (for example,
CQ or CQ plus SP);
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b. there were many different artemisinin derivatives and combinations tested, with few trials of each, so these were grouped within the
same comparison. We also grouped combinations of an artemisinin derivative with SP here.
3. There were no eligible cluster-RCTs so we deleted how we would manage them from the Methods section. If we include any cluster-
RCTs in future editions, we will check that trials have correctly adjusted for clustering and, if not, attempt to make this adjustment.
When the analyses have not adjusted for clustering, we will attempt to adjust the results for clustering by multiplying the standard
errors of the estimates by the square root of the design effect, where the design effect is calculated as DEff=1+(m-1)*ICC. This assumes
that the necessary information is reported, the average cluster size (m) and the intra-cluster correlation coefficient (ICC).
4. We intended a sensitivity analysis to investigate the robustness of the results to the quality (risk of bias) components, but were unable
to do so as there were insufficient trials. If appropriate and necessary, we will conduct sensitivity analysis on cluster-RCTs using a range
of estimates for the ICC to see if clustering could influence the individual trial’s result.
2015 version
5. Comments on the review were addressed (see below). An updated search did not identify any new trials for inclusion.
2018 version
6. In 2018 we removed some secondary outcomes including our AUC calculations, asexual stage outcomes, and gametocyte prevalence
outcomes at time periods after day 8, given new higher priority evidence and comparisons. AUC if reported by trials is still included.
We removed the following secondary outcomes that were in the 2015 version:
• Presence of asexual stage parasites (may be reported as treatment failure rate);
• Asexual parasite clearance time (duration of asexual carriage).
We also restricted infectiousness and gametocyte prevalence outcomes to day 8 of follow-up. We excluded any trial arms with < 0.2
mg/kg PQ (three arms). We converted analysis figures of infections acquired by mosquitoes to tables.
N O T E S
We received comments from Professor Nick White, who has published extensively on using PQ to prevent transmission. Professor
White sent some helpful comments on the use of the data and its interpretation. These were considered by the authorship team and
disaggregated into key points that needed to be addressed by the review. The Cochrane Contact Editor moderated the process. The
main points raised and addressed were:
1. The lack of effect in low dose categories of PQ does not mean there is no effect and the data suggests a dose response
relationship. Response: we have adjusted the wording within the review.
2. Data from Pukrittayakamee 2004 has been incorrectly extracted/interpreted. Response: Two review authors working
independently assumed “after treatment” meant after the seven day course, and it was helpful to have it clarified that this was not the
case. Therefore we excluded the data for day 8 gametocyte prevalence from this analysis. We inserted additional text on the
gametocyte clearance time and duration of gametocyte carriage to the Results section.
Professor White’s comments subsequently appeared in a publication about the topic (White 2014). We corrected all points of factual
detail in the 2015 review version.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [∗administration & dosage]; Artemisinins [administration & dosage; therapeutic use]; Chloroquine [therapeutic use];
Drug Combinations; Glucosephosphate Dehydrogenase Deficiency [∗diagnosis]; Malaria, Falciparum [parasitology; ∗prevention &
control; transmission]; Mefloquine [therapeutic use]; Plasmodium falciparum [drug effects]; Primaquine [∗administration & dosage];
Pyrimethamine [administration & dosage]; Quinine [therapeutic use]; Randomized Controlled Trials as Topic; Sulfadoxine [adminis-
tration & dosage]
MeSH check words
Humans
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